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Abstract

Actinobacteria, primarily the genus Streptomyces, have led to the development of a number of
antibiotics, which result from their secondary metabolites or modified derivatives. Secondary
metabolite production can result from competition with neighboring microbes in an effort to
disrupt growth, aiding in the competition for vital nutrients in impoverished conditions. Such
secondary metabolites have the potential to affect a plethora of cellular functions in target cells,
including, cell wall development, protein synthesis, protein function and fatty acid
synthesis/metabolism. Due to the pandemic spread of antibiotic resistant bacteria, it is
imperative to continue the search for new therapeutic agents targeting these deadly organisms.
As such, our group explored soil and marine samples from Tampa Bay’s surrounding farmlands
and waterways for secondary metabolite producing microbes using culture methods specific to
Actinobacteria. Through these efforts we isolated over 750 bacterial species, of which almost
half are confirmed Actinobacteria. In an attempt to derive new and novel chemistry from these
organisms, we used our novel collection, and developed techniques for epigenetic modification
to un-silence dormant and cryptic metabolic pathways. Our work reveals that a number of these
Actinobacteria produce secondary metabolites that are effective against the ESKAPE
pathogens, some at very low concentrations. Although the bioactivity from secondary
metabolites is a well-known source for antibiotic drug discovery, our epigenetic methods
suggest a potential to isolate previously overlooked compounds that have a very real possibility
for use as antibacterial therapeutics.

v

Introduction

Antibiotics: Costs and Resistance.
Some of the greatest advances in healthcare have been the advent of antimicrobial agents that
are safe and effective. This therapeutic option has been associated with winning wars or
prolonging life and is an essential part of modern medicine. Through the development of
antibiotics human kind has had the benefit of increased food production in the form of
preventing large-scale infections that wipe out entire populations of livestock. Anti-infective
agents have also allowed for the advancement of surgeries including invasive procedures that
may not have been available for fear of disease. There is however, a rather large caveat, which
is antibiotic resistance. This issue is not limited to third world countries, it occurs on a global
scale, in fact there were over two million antibiotic resistance infections and roughly 23,000
antibiotic resistance related deaths in the United States in 2013 (1). Antibiotics can be described
as a double-edged sword being that using them is what drives resistance. While we constantly
struggle to identify novel therapeutics, bacteria have inadvertently found numerous mechanisms
for escaping the threat of antimicrobials. Bacteria have not only developed resistance to one
antibiotic, but have acquired resistance to numerous antibiotics simultaneously, thus bringing
about multi-drug resistance and even pan-resistance as seen in Acinetobacter baumannii
isolates (2). Antimicrobial resistance does not only affect fitness of humans and microbes, but it
also creates an extreme economic burden for humanity. Estimates suggest direct healthcare
costs as high as $20 billion and lost productivity costs as high as $35 billion annually (3).
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There are numerous arguments for how humanity may have misused antibiotics including
overuse, inappropriate prescriptions, and use in agriculture. One of the biggest issues with
regards to antibiotic resistance is the extensive overuse of these drugs (1). As mentioned
earlier, resistance is acquired through the use of antibiotics, however it seems as though this
occurrence could have been delayed if antibiotics were not issued unnecessarily. Antibiotic
resistance could also be delayed if there were less of a need for antibiotics, this could easily be
achieved if humanity were proactive with regards to infection prevention. Inappropriate
prescriptions play a gargantuan role in antibiotic resistance as research has estimated that
antibiotics are either misused or unwarranted 50% of the time (1). Failure to provide accurate
prescriptions by doctors may not even provide relief for the patient, and is causing an extreme
level of detriment for the future of humanity. In a 2015 Food and Drug Administration report,
71% of antibiotics sold in the United States were for use in food animals as an aid for production
or production/therapeutics while the remaining 29% was used for as a therapeutic only (4). This
staggering statistic is known to play a role in antibiotic resistance in many forms including
emerging antibiotic resistant organisms and organisms that have acquired much higher
tolerances to current antibiotics (5). It is impossible to know what could have been if humanity
had used antibiotics appropriately, however in the generation leading up to a potential postantibiotic era, we may yet rectify some of these deleterious effects.

ESKAPE Pathogens
Since the discovery of penicillin by Alexander Fleming, humanity has entered a non-stop
struggle against the constant flow of evolution and genetic transfer that microbes rapidly
undergo. This genomic flexibility seen in bacteria has led to an increase of antibiotic-resistance,
which has resulted in the need for new bioactive therapeutic compounds (6). The increase in
resistance is associated with the overuse of antibiotics, negligent patients and a
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misunderstanding of how microbes play an important role governing our homeostasis (7). A
group of bacteria, commonly associated with human infection that have developed the ability to
escape the antimicrobial effects of modern antibiotics, have been termed the ESKAPE
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa and Enterobacter species) pathogens by the Infectious
Disease Society of America (IDSA) (7). These ESKAPE pathogens comprise the majority of
nosocomial-acquired infections in the United States (8).

Enterococcus faecium is a Gram-positive, facultative anaerobe and opportunistic pathogen,
which reside within the digestive tract of animals. It is a non-spore forming member of the
Firmicutes, which are characterized by their low G+C content (9). Prior to 1984, this bacterium
was known as Streptococcus faecium (10). E. faecium infections can result in pelvic and urinary
tract infections as well as endocarditis (11). Enterococci are well equipped with intrinsic
resistance to a number of antibiotics such as aminoglycosides, and are able to mutate or
acquire genes in order to deal with other antibiotics, such as β-lactams (12, 13). Prior to the mid
1980s vancomycin resistant E. faecium was unheard of, but as of 2007 more than 80% of E.
faecium isolates possessed vancomycin resistance (14). E. faecium doesn’t possess the level of
pathogenic potential as other organisms such as Staphylococcus aureus, however, it is proving
to be quite problematic as it has demonstrated resistance to almost every antibiotic used for
enterococcal infections (12, 14).

Staphylococcus aureus is a Gram-positive, facultative anaerobe and opportunistic pathogen,
which can reside on the skin, or within the anterior nares and throat of humans and also a wide
range of animals (15). It is a non-spore forming member of the Firmicutes (9). S. aureus has
been a major public health concern for a long while and is the leading cause of foodborne
illness worldwide (16, 17). Staphylococci are also well known for their ability to acquire
3

resistance to harsh antibiotics such as methicillin or vancomycin as well as the speed with which
they acquire such resistance. There are numerous mechanisms with which S. aureus is capable
acquiring resistance, such as hydrolytically cleaving a compound as seen in β-lactam antibiotic
resistance, or alteration of their architecture in order to prevent binding of compounds as seen
with glycoside antibiotic resistance (18). Some of the components that make S. aureus such a
threat are the variety of virulence factors, toxins as well as the ability to survive host immune
responses (19).

Klebsiella pneumoniae is a Gram-negative, facultative anaerobe and opportunistic pathogen,
which can reside in the mouth, intestines and other mucosal surfaces of healthy humans (20).
K. pneumoniae can also naturally reside within the soil (21). It is a non-spore forming member of
the Proteobacteria, specifically the Gammaproteobacteria, which includes numerous medically
relevant groups of bacteria (22). Majority of K. pneumoniae isolates possess a capsule which
helps the bacterium evade the immune system (23). Colistin has been a last resort antibiotic for
K. pneumoniae infections, but with the rise in carbapenum resistance, colistin became a
necessary treatment option for carbapenum-resistant K. pneumoniae (24). As a result of the
continued use of colistin, we are now seeing colistin resistance amongst this bacterium, which
will eventually leave humanity vulnerable again (24).

Acinetobacter baumannii is a Gram-negative, facultative anaerobe and opportunistic pathogen,
which resides almost exclusively on humans, unlike other Acinetobacter species, which reside
within soil, water and animals (25). It is a non-spore forming member of the Proteobacteria,
specifically the Gammaproteobacteria (22). A. baumannii can cause numerous infections
including skin and soft tissue infections, wound infections, urinary tract infections and also has
been implicated in pneumonia as well as septicemia (26, 27). Resistance to a broad spectrum of
therapeutics has been seen in A. baumannii including beta-lactam, quinolone and
4

aminoglycoside antibiotics (28). These antibiotics are dealt with in a number of ways, including
enzyme degradation, as seen in beta-lactam antibiotics, mutations and highly active efflux
pumps, as seen with quinolone resistance, or enzyme modification, as seen in aminoglycoside
resistance (28).

Pseudomonas aeruginosa is a Gram-negative, facultative anaerobe and opportunistic pathogen,
which can reside in almost any environment including soil, water, animals, humans, and plants
(29).

It

is

a

non-spore

forming

member

of

the

Proteobacteria,

specifically

the

Gammaproteobacteria (22). One of the biggest concerns for this bacterium is the low nutrient
requirements as well as its uncanny ability to escape antibiotic effects (30). Of the mechanisms
for antibiotic resistance, over active efflux pumps play a significant role in preventing drugs from
reaching their targets (31). Other mechanisms for antibiotic resistance include modification of
drugs or drug targets (31).

Enterobacter cloacae is a Gram-negative, facultative anaerobe and opportunistic pathogen,
which can reside in the gastrointestinal tract of humans as well as throughout the environment
(32). It is a non-spore forming member of the Proteobacteria, specifically Gammaproteobacteria
(22). E. cloacae was originally thought to occur as a nosocomial agent from the environment or
hospital staff, however it was later concluded to be a result of the patients own microflora (33). It
has been demonstrated that E. cloacae possesses resistance to ampicillin and a number of
cephalosporin antibiotics, and has the potential to mutate in order to acquire alternative
antibiotic resistance (32).

There are many ongoing debates as to which acquisition of infection type is worse, community
acquired, or hospital acquired. Some suggest that hospital acquired infectious agents possess
less virulence, but are more robust and difficult to treat and therefore impossible to completely
5

eradicate from the host (34). Others pose that community acquired infectious agents have had
limited exposure to antibiotics and are more virulent suggesting that disease onset is much
more rapid (34). Original thoughts were that hospitals provided the optimal environment for
infection as residents were often ill or had some form of immune deficiency (35). This is no
longer the case as number of community acquired infectious agents is on the rise and one
mathematical model suggests community acquired methicillin-resistant S. aureus will
outcompete hospital acquired strains (36). Many reports from hospitals suggest that community
acquired strains include the ESKAPE pathogens among others (37, 38). A study of methicillinresistant S. aureus diagnoses in 2013 from California hospitals reported that 1 in 100 inpatient
stays possessed a primary or secondary diagnosis (39).

Antibiotic Resistance Mechanisms
There are many methods by which bacteria confer antibiotic resistance. Methods that are
utilized by many different bacteria include reduced uptake of antibiotic, antibiotic target
modification by mutation or chemical modification, antibiotic modification, overproduction of
antibiotic target, enzymatic degradation or efflux of antibiotic (Figure 1). Even with this torrent of
antibiotic resistance mechanisms, we still have numerous classes of therapeutics that maintain
some level of potency today. The antibiotic class that includes sulphonamides, which are still
synthetically derived today, need perpetual alterations, as microorganisms continuously acquire
resistance, furthermore, a large portion of the human population have allergies to sulpha drugs
(40). Sulphonamides are typically used today for treatment of urinary tract infections, as they
are broad spectrum and target folate synthesis. Other antibiotic classes used in medicine today
include β-lactams (penicillins, cephalosporins, carbapenums etc.), which have undergone
numerous structural evolutions through the years, target the bacterial cell wall (41, 42).
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Antibiotic

a.
Impaired Influx

b.

Target Modification/
Mutation

c.

Drug
Modification

e.

d.

Overproduction
of target

f.

Efflux

Drug Degradation

Figure 1. Antibacterial Resistance Mechanisms
Resistance to antibacterial compounds can e achieved in a number of ways. Drugs are not able
to permeate through the membrane (a); drug target is modified or mutated (b); drug is modified
(c); drug target is overproduced (d); drug is enzymatically degraded (e); effluxed immediately
after entry (f).
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Amendments to β-lactam antibiotics primarily involve prevention of enzymatic degradation via βlactamase, by addition of substituents that “shield” the β-lactam ring structure (41).

Reducing the uptake of a harmful compound ensures it will never reach its designated target. All
antibiotics, regardless of their mechanism of action require some form of uptake into the cell;
therefore permeability plays an important role in antibiotic efficiency. Gram-negatives possess a
secondary membrane, which provides an extra layer of protection from permeable and semipermeable compounds. Reducing permeability in Gram-negatives outer membrane proteins
also limits antibiotic entry (43). In Enterobacteriaceae, it was seen that there was a reduction in
carbapenemase expression, the enzyme responsible for enzymatic degradation of carbapenem,
yet the bacteria were still exhibiting resistance to the antibiotic (44). It was determined that there
was selective pressure by carbapenum that caused a mutation in porin expression genes (45,
46) (Figure 1a).

Antibiotics are target specific in that they bind with extreme prejudice to specific sites thereby
inhibiting or reducing normal function. Subtle changes to the target site and still allowing for
normal function can provide partial or complete resistance to the antibiotic. In an infection, there
are many different subpopulations within the overall population. If a single point mutation were
to occur in the gene of an antibiotic target, this could be the difference between surviving or
succumbing to the onslaught. This has been demonstrated with linezolid resistance in S.
aureus. Single nucleotide mutations in S. aureus’ genes encoding the 23S rRNA ribosomal
subunit prevents binding of linezolid, but does not inhibit function and thereby conferring
antibiotic resistance (47, 48). Modifications that result in resistance do not always occur by
mutations, they can also occur via transformation, or uptake of foreign DNA from the
environment that results in “mosaic” genes. An example of such a phenomenon occurred in
8

Streptococcus pneumoniae with regard to penicillin resistance. S. pneumoniae acquired genes
which encode penicillin binding proteins that possessed a reduced affinity towards penicillin
(49). Another example occurred in methicillin resistant Staphylococcus aureus in which the
bacterium acquired a staphylococcal cassette chromosome mec element, which allowed S.
aureus to produce β-lactam insensitive penicillin binding protein (50). Acquisition of this
insensitive penicillin binding protein allowed for cell wall synthesis to continue as indigenous
penicillin binding proteins were inactivated by present antibiotics (50) (Figure 1b).

Modification of antibiotic target using the addition of a small chemical group can be just as
beneficial to bacteria as mutations or acquisition of modified target genetic material. One
method that bacteria have established in the war against antibiotics is methylation of the target
site. An example was observed with regard to erythromycin resistance whereby the
erythromycin ribosome methylase (erm) family of genes would methylate the 16S rRNA
ribosomal subunit (51, 52). Another instance where methylation conferred resistance has been
observed in chloramphenicol resistance which involves the chloramphenicol-florfenicol
resistance (cfr) methyltransferase enzyme transferring a methyl group to the 23S rRNA
subunit’s active site to prevent drug binding not only for chloramphenicol, but to a number of
drugs that rely on this site for inhibition (53-55). Modification of drug targets is not limited to
methylation, but can also occur with proteins that bind with higher affinity than the drug or bind
to facilitate release of the drug. With regard to quinolone resistance, qnr genes encode
pentapeptide repeat proteins that can bind to the topoisomerase-quinolone complex and result
in the release of the antibiotic (56) (Figure 1c).

Bacteria have not only unlocked methods modify self to prevent antibiotic binding, but they have
also ascertained approaches to modify the antibiotic compound itself. Addition of chemical
groups to an antibiotic can result in resistance to the drug. Bacteria modify antibiotics with
9

proteins called “resistance enzymes,” which transfer chemical groups to the drug. Group
transfer can include acetylation, phosphorylation thiol transfer among others. Acetylation as a
drug modification system has been seen with aminoglycosides, which prevents the drug from
binding to the ribosome (56). Due to their nature, aminoglycosides possess many substituents
that can be modified in different ways including phosphorylation, which also prevents the drug
from binding to the ribosome (57). Phosphorylation modifications can occur on other antibiotics
as well; macrolides such as erythromycin are also susceptible to this modification, which
prevents interaction with the 23S rRNA ribosomal subunit (58-60). Thiol transfer inactivation of a
drug has been seen in fosfomycin resistance, through which the bacteria can resume
peptidoglycan biosynthesis (61). It has been found that a number of these resistance enzymes
are plasmid encoded and perhaps originated in the bacterium that produced the antibiotic (61).

A technique used by bacteria to overcome the barrage from antibiotics includes an
overproduction of the drug target. Additional production, higher than standard levels, can result
in antibiotic resistance as seen with trimethoprim resistance. Typically overproduction of the
drug target seems to be pure circumstance. Random mutations in the promoter region of the
gene can lead to more efficient binding of the RNA polymerase, which results in higher levels of
transcription of the gene. Alternatively, random mutations to the ribosomal binding site can yield
the same outcome as more of the mRNA is then translated. In the case of trimethoprim
resistance in Escherichia coli, both of these events occurred which resulted in an
overproduction of dihydrofolate reductase, which is used for tetrahydrofolate production, an
important cofactor in amino acid and nucleotide biosynthesis (62). This overproduction allowed
for trimethoprim sequestration as well as cellular functions to continue normally (Figure 1d).

Since resistance to antibiotics cannot always be obtained through modifications or mutations,
bacteria have also demonstrated numerous methods for the destruction of the drugs. Enzymatic
10

destruction has occurred in bacteria since the introduction of penicillin in 1943 by Alexander
Fleming (5). There are a wide variety of β-lactamases, which are able to hydrolyze most of the
β-lactam antibiotics such as penicillins, cephalosporins, and carbapenums (41, 42). Attempts
have been made to modify β-lactam antibiotics to provide more rigid structures that are less
prone to degradation, however bacteria have still demonstrated resistance. An example of such
a modification is seen with oxyimino-aminothiazolyl cephalosporins where the β-lactam ring is
typically sheltered from hydrolysis, however β-lactamases found in K. pneumoniae have
demonstrated hydrolytic capabilities (41, 63) (Figure 1e).

Another proficient method of escaping the effects of antibiotics is to remove the drug from the
cell before it has a chance to reach its target. Efflux pumps are transporters that provide such
an act. Many times antibiotics that have bacteria specific targets only affect Gram-positives due
to the effectiveness of efflux pumps found in Gram-negatives. Overexpression of efflux pump
related genes can provide a significant advantage and ensure high levels of resistance (64)
(Figure 1f).

Actinobacteria
The name Actinomycetes was first proposed in 1916 as a way to categorize bacteria (65).
Originally known as the “thread” bacteria, which possess a filamentous form and share very
similar characteristics to filamentous fungi, Actinobacteria have had many changes with regards
to taxonomy overtime (65). This phylum exhibits great diversity with regard to varying
morphologies, physiologies, and metabolism. As one of the largest phyla it contains six classes,
which are composed of 22 orders. The largest class, Actinobacteria, possesses 15 of the orders
and is made up by 43 families (66). Actinobacteria are Gram-positive filamentous bacteria that
typically possess high G+C genomic content (66). Actinobacteria can be spore and non-spore
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forming and occupy almost all ecological niches including terrestrial, aquatic, and plant or
animal associated as either pathogens or commensals (67, 68) Many organisms within this
phylum have very diverse secondary metabolism, which has been and continues to be exploited
by humans for use in biotechnology, medicine and agriculture. By appearance, many closely
resemble filamentous fungi as majority of the Actinobacteria develop mycelia and reproduce via
sporulation. The varying morphologies of Actinobacteria can include coccoid, short-rod, or
branched filaments and can possess substrate mycelia, aerial hyphae, both or neither. Spore
formers can produce in spore chains containing as many as two through 100’s of spores, or as
singular spores (69).

Actinobacteria life cycle varies greatly between the classes, however many that include
sporulation in their lifecycle such as Streptomyces, begin as a free spore. Spore germination
occurs and leads to vegetative growth and development of substrate mycelium. As nutrient
levels begin to dwindle, aerial hyphae begin to form and finally spore formation occurs, however
spore formation can occur without the presence of aerial hyphae (69). Streptomycetes and other
Actinobacteria do not divide via elongation of the lateral wall as seen in other rod shaped
bacteria such as Escherichia coli or Bacillus subtilis, instead they replicate via tip extension (7072). Cell wall synthesis occurs at the tip of the growing bacteria due to DivIVA accumulation (70,
71). These tip extensions are segregated into compartments which results in multi-chromosomal
filaments which penetrate the substrate known as substrate mycelium (72, 73).

Actinobacteria are characterized via the 16S rRNA gene, which can organize isolates into their
respective genera, it is difficult to discern between closely related genera or species. Genome
sizes can vary from as small as 0.93 mega base pairs seen in Tropheryma whipplei to 12.7
mega base pairs seen in Streptomyces rapamycinicus (74, 75). Small genome size is thought to
be a result of genome compaction as the bacteria adapt to a host, which provides a relatively
12

unchanging environment (74). Conversely it is theorized that strains that remain the open
environment such as soil maintain their large genome size in order to acclimate to constant
change and potential threats (74).

The secondary metabolism of Actinobacteria is remarkably diverse and has provided roughly
two-thirds of all antibiotics as either native natural products or as natural product derivatives
(76). Secondary metabolites are not only classified as antibiotics, they play an immense role in
the survival of Actinobacteria. Aside from killing or inhibition of other microorganisms, they can
aid in metal acquisition, and even have toxic affects against plants and animals (77). It is
thought that the number of secondary metabolites being produced by specific bacterium is a
mere fraction of the biosynthetic potential of these bugs (78). Gene clusters within the genome
that are not expressed under normal growth conditions and cannot be isolated are typically
referred to as cryptic or silent. Actinobacteria in the environment come into contact with an
enormous variety of organisms, including insects, plants, bacteriophages, fungi, and of course
other bacteria. Interactions with any of these organisms, or their respective metabolites, could
initiate a cascade of transcriptional machinery for cryptic or silenced biosynthetic pathways. It
was found that within Streptomyces coelicolor alone actinorhodin, streptorubin B, geosmin, 2methylisoborneol,

albaflavenone,

calcium-dependent

antibiotic

2a,

desferrioxamine

E,

coelimycin P1, methylenomycin A, germicidin A, coelichelin, Streptomyces coelicolor
butyrolactone

1,

methylenomycin

furan

1,

TW95a,

flaviolin

dimer,

aminotrihydroxybacteriohopane, and isorenieratine could be produced, each of these belonging
different classes of secondary metabolite (78-80). In a study of the whole genome of one of the
best-characterized Actinobacteria, Streptomyces coelicolor, Bentley et al. described almost 20
theorized secondary metabolite biosynthetic pathways (78). The biggest complication lies within
identifying appropriate conditions necessary for transcription of said biosynthetic pathways (78).
Large strides have been made in a global effort for the search of novel chemistry from
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Actinobacteria including methods such as co-cultivation, genome mining and chemical or small
molecule induction (81). Co-cultivation is thought to better mimic environmental interactions of
the Actinobacteria. One study demonstrated N-acetylglucosamine, a cell wall component of
bacteria, could induce more production of actinorhodin in S. coelicolor (82). Genome mining
involves scouring the entire genome of one bacterium in search for homologous genes to those
that have already been annotated for use in secondary metabolite biosynthesis. Bentley et al.
utilized this method in unearthing the 20 theorized secondary metabolite biosynthetic pathways
(78). Chemical or small molecule induction practices suggest that introduction of a chemical
agent can alter the secondary metabolite production of a bacteria. Varying concentrations of
dimethyl sulfoxide were used on three different Streptomyces strains and demonstrated
increased compound production (83).

Natural Products
The field of natural products chemistry encompasses any chemical substances produced by a
living organism, however it is notoriously associated with chemical substances that have a
pharmacological effect. Before modern medicine, natural products were applied in the form of
crude pastes or teas, such as willow bark, which contains salicylic acid, better known as aspirin
(84, 85). With the discovery of penicillin in 1928 and its introduction in the early 1940s, natural
products chemistry morphed into what we now know as the field of antibiotics (86). Shortly after
the introduction of penicillin, Actinobacteria entered the scene with the discovery of actinomycin
in 1940 by Selman Waksman from a soil organism, Actinomyces sp. (87, 88). Waksman spent
many years looking at soil content and resident organisms as far back as 1916 in search of
whether soil organisms grew the same way in their natural environment as in the laboratory
(89). The early years of natural product drug discovery focused on industrial scale culturing of
microorganisms in the search for potential therapeutics (90). The time between the 1940s and

14

1960s are regarded as the “golden age” of antibiotics, where many of the classes of antibiotics
we know today were discovered (91). This fleeting moment of history was over all too soon; as
humanity entered the 1970s changes were being made in science, medicine and the economy.
Antibiotics were becoming increasingly expensive to pursue and too often were they rediscovered (76). We have since left the golden age of antibiotics and entered into a state with
which a post-antibiotic era is a potential and terrifying scenario (7). While natural products are
still providing as a prolific source of antibiotics, the rigor required for FDA approval combined
with the rate of antimicrobial resistance is proving a herculean task (5). Antimicrobial resistance
in a few cases has even been identified prior to the introduction of an antibiotic, such as
penicillin resistance, which was observed in 1940 and the drug released three years later (5).
Current drug pipelines involve the process of screening for products, finding an extract that
possesses some form of biological activity, purifying the compound and elucidating the
structure, followed by rigorous testing to ensure it maintains activity in its purified state, all of this
before the compound is even considered for medicinal chemistry (Figure 2). After all of the
preliminary data is acquired, compounds can eventually make their way to clinical trials, which
could take roughly 15 years, if the drug passes all three phases (92). Aside from the timeline,
the average cost of introducing a drug in modern medicine averages almost $2.6 billion (92). As
a result of the financial burden and the life span, a number of pharmaceutical companies
downsized their natural product divisions and changed focus to synthetic chemistry and the
introduction of combinatorial chemistry (90). However there are still many programs that exist
today that focus on natural products, which is due to nature’s imagination acting better than any
synthetic chemist. The field has evolved through the years to include modern techniques such
as high-pressure liquid chromatography (HPLC) and mass spectrometry (93).

An enormous challenge with natural products drug discovery involves the timeline; in order to
find a potential therapeutic, it must first be produced by nature. Alternative approaches
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mentioned earlier describe current techniques used to modify organisms in an attempt to
produce alternative chemistry including chemical, biological or genomic elicitation (78, 82, 83).
Another issue lies within the screening of natural product extracts, which usually contain an
amalgam of compounds, some which may present issues later in the purification process (90).

Regardless of the daunting reputation of natural products chemistry, it has still provided
antibiotics such as penicillin, streptomycin, polymyxin and many more, which are used in the
treatment of infectious disease. The alarming rate of resistance developing continually
challenges humanity to develop new therapeutics. Of the ~500,000 natural product derived
compounds discovered up until 2012, 20% are animal derived, 70% are plant derived, and 10%
are microbial derived (76). Although natural products can be isolated from animals and plants,
bioactivity is seen from only three and seven-percent, respectively, while 47% of microbial
derived natural products maintain bioactivity (76). Roughly 37% of all microbial derived bioactive
metabolites are identified from bacteria of the order Actinomycetales (76).

DNA Methyltransferase
Of the many regulatory mechanisms possessed by bacteria, methylation is extremely fast as
well as efficient. Methylation of DNA provides numerous benefits including control of DNA
replication and regulation of cell cycle; indication and administration of mismatch repair, as well
as distinguishing self from foreign DNA (such as bacteriophage) (94-96). DNA methylation
occurs via enzymes known as DNA methyltransferase. DNA methyltransferases are ubiquitous
in nature and occur in all domains of life. There are three primary targets of DNA
methyltransferases, which leave behind methylated base pairs. C5 methyl-cytosine possesses a
methyl group on the on the fifth carbon position; this is seen most commonly in Eukaryotes, but
can occur in bacteria, however not very often (97). N6 methyl-adenine possesses a methyl
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Figure 2. Traditional Pipeline for Drug Discovery
The natural product is extracted from a biological source and tested for bioactivity then purified.
The structure is determined and a mechanism of action is established. Novel compounds are
scaled or tested to determine if synthetic derivatives can be produced. Once a feasible method
for scaled production is determined, the compound proceeds to additional optimization and
eventually medicinal chemistry.
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group on the sixth nitrogen position; this is seen most commonly in Prokaryotes and lower
eukaryotes, but not in vertebrates (97). N4 methyl-cytosine possesses a methyl group on the
fourth nitrogen position; this method of methylation has only been seen in bacteria thus far (97).
All DNA methyltransferases utilize S-adenosine-L-methionine (SAM) as the methyl donor. In the
case of C5 methyl-cytosine the transfer of a methyl group begins with a nucleophilic attack by a
thiol group (found within the protein complex) on the sixth carbon on a cytosine base, which will
result in the transfer of a methyl group from SAM (found within the protein complex), after this
transfer a β-elimination reaction will release the DNA methyltransferase from the DNA leaving
behind a methylated cytosine base (Figure 3A) (98).

Epigenetic Modification
Since Actinobacteria have historically been such a prevalent source of bioactive compounds,
scientists have exploited many novel techniques for exploring their genomes with the hopes of
finding novel secondary metabolites (91). Techniques, such as whole genome sequencing,
have changed the way we look at organisms, such that we can now analyze an organism’s
chromosome and determine homologous genes. This phenomenon was observed with S.
coelicolor, when Bentley et al. scoured the chromosome for any biosynthesis genes that may be
to known bioactive secondary metabolite biosynthesis associated genes and found over 20
gene clusters that were known or hypothesized to code for secondary metabolites (78). One of
the difficulties with such findings; it raises the question “how can the organism be modified to
ensure these cryptic biosynthetic pathway genes are expressed?” The task of ensuring genetic
expression sounds daunting enough, but then the transcribed genes also need to exercise their
intended function. There are two very generalized approaches to such a challenge 1) pick a
specific organism and a target within that organism then begin modifications or 2) prepare a
universal technique that can be performed in a high throughput fashion. Both approaches are
18

A) Standard Cytosine Methylation
H

DNA methyltransferase
release

B) DNMTi Methylation
H

DNA methyltransferase
degradation
Figure 3. Mechanisms of DNA Methyltransferase
DNA methyltransferase enzymes possess a thiol group, which allows for a nucleophilic attack
on the carbon in the sixth position of a cytosine base and through multiple steps of electron
transfer a methyl group is transferred from SAM to a carbon in the fifth position of the cytosine
base, finally a β-elimination releases the enzyme (A). Using a DNA methyltransferase inhibitor
which resembles a cytosine base, the same nucleophilic attack from the thiol group to the
carbon in the sixth position and through multiple steps of electron transfer a methyl group is
transferred from SAM to a nitrogen in the fifth position, finally there are no further reactions that
can take place and the enzyme is unable to be released resulting in its degradation (B).
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utilized throughout the world today; however there have been a number of successes identifying
novel compounds from well-characterized organisms using epigenetic modification (99, 100).

Epigenetic modification, looking at differences in an organism due to changes in gene
expression, involves the addition of a chemical agent designed to inhibit genetic modifiers such
as methyltransferase or histone deacetylase, in order to prevent proper gene regulation (99,
101). Proper gene regulation is disrupted when an epigenetic modifier, such as a DNA
methyltransferase inhibitor, prevents methylation of specific regions near or within gene
promoter regions. This lack of methylation has the potential to increase the affinity with which
transcription machinery binds to the promoter regions (102). Substances such as 5-azacytidine
can be used as a DNA methyltransferase inhibitor (DNMTi). 5-azacytidine will be converted
upon entrance to 5-azacytosine, a molecule analogous to the DNA base pair, cytosine. The
difference between the two is in the fifth carbon position of cytosine, which has been replaced
with nitrogen. This subtle change in the molecule still allows for methyl transfer, however
prevents the DNA methyltransferase enzyme from dissociating, which results in degradation as
well as eliminating the enzyme from the cellular environment (97) (Figure 3B). Literature
searches suggest that epigenetically modifying organisms for elicitation of secondary
metabolites has been limited primarily to fungi (100, 103-106). Under a variety of laboratory
growth conditions Aspergillus niger will suppress transcription of more than 70% of the gene
clusters dedicated to secondary metabolite biosynthesis (106). Using a histone deacetylase
inhibitor, Henrikson et al. were able to demonstrate variation of A. niger’s secondary
metabolome with the identification of a novel secondary metabolite, nygerone A (106).

These methods for fungal epigenetic modification have utilized primarily DNA methyltransferase
inhibitors and histone deacetylase inhibitors. Bacteria do not possess histones; instead they
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possess DNA-binding histone-like proteins such as HU or H-NS found in E. coli. There have
been examinations of the effects of histone deacetylase inhibitors on prokaryotes, which have
exhibited variations in gene expression levels, although the mechanism by which this occurs is
not fully understood, and therefore we focused our efforts on the DNA methylation (107).
Although the literature primarily describes fungal epigenetic modification, bacterial epigenetic
modification literature is also available. Kumar et al. found that epigenetically modified S.
coelicolor possessed an additional major protein band when compared to the unmodified control
(108). There were also differences within the HPLC chromatogram as the crude extract from the
modified bacterium demonstrated 12 compounds and unmodified only displayed five (108).
Another group looked at antibiotic production in bacteria using kinase inhibitors and cell
transport regulators as a form of epigenetic modification and found that one of the kinase
inhibitors actually increased production (109).

Using a DNA methyltransferase inhibitor, we believe a collection of Actinobacteria can be
modified and extracted in a high throughput screen. We anticipate that by altering the epigenetic
regulatory enzymes, the well-characterized strains will be unable to properly regulate previously
unidentified and highly sought after genetic pathways, yielding new bioactive secondary
metabolites (Figure 4).

Anthracyclines
The first anthracycline was isolated from Streptomyces peucetius and titled daunomycin or
rubidomycin, however quickly changed to daunorubicin (110-112). Farmitalia Research
Laboratories of Milan, Italy and the French firm of Rhóne Poulenc of Paris, France founded
daunorubicin. The compound received its name for Daunii, a pre-Roman tribe where to soil
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Figure 4. Potential Outcome of Demethylation
Control possesses methyl groups along DNA, which prevents transcription of potential
secondary metabolite biosynthesis pathways or their products. Using a DNMTi effectively
prevents methylation of DNA, which allows transcription of potential secondary metabolite
biosynthesis pathways or their products. Presence or absence of methyl groups on DNA can
either induce or repress transcription.
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sample was collected, and rubis, the French word for ruby (113). Since the introduction of
anthracyclines in the 1960’s, many more have been discovered and synthesized including
analogs such as doxorubicin (Adriamycin), epirubicin, or idarubicin. Many anthracyclines have
been approved for use throughout the world, however doxorubicin was the first to be approved
by the Food and Drug Administration in the United States. The only difference between
daunorubicin and doxorubicin is a single hydroxyl group (Figure 5). This subtle change seems
insignificant, however both compounds display different anti-tumor activity (111). Since this
subtle change in structure resulted in changes in anti-tumor activity, chemists have synthesized
anthracycline analogs with numerous variations on the original structure.

Anthracyclines are characterized as intercalating agents that possess anti-tumor activity as well
as mild Gram-positive antibacterial activity (110). This class of antibiotic has been ranked as
one of the most effective anti-cancer drugs ever developed and the most utilized worldwide
being doxorubicin (113). A major drawback of anthracycline compounds is the inevitable
cardiotoxicity. The search and creation of new anthracyclines is held to the standard of
doxorubicin, whereby the anti-tumor activity is assessed, followed by the cardiotoxicity.
Compounds that exhibit any combination of anti-tumor activity or cardiotoxicity that would be
more severe for a patient are dismissed.

A number of methods by which anthracyclines are effective have been proposed, including
prevention of topoisomerase II from binding to DNA due to anthracycline intercalating ability,
inhibition of religation of DNA after a double strand or single strand break from topoisomerase
(114), induction of apoptosis, or free radical generation (115). It is thought that anthracyclines
inhibit growth of bacteria using similar mechanisms to those seen in humans (116). Inhibition of
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Daunorubicin

Doxorubicin

Figure 5. Comparing Two Anthracyclines
Daunorubicin possesses a basic acetyl substituent on the D ring while Doxorubicin is identical
except for the hydroxyl substituent attached to the acetyl residue. This subtle change provides
significantly higher anti-tumor bioactivity.
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growth in bacteria is limited to the Gram-positive organisms, and studies have shown sensitivity
to anthracyclines in Gram-negative bacteria lacking efflux systems (117).

Project Aim
One of the major issues humanity faces is the potential of a post-antibiotic era, where currently
effective drugs, will no longer be useful and diseases that have been maintained for over 75
years will once again wreak havoc. Natural products have provided many potential therapeutic
options throughout the years as well as scaffolds for natural product derivatives. We know that
Actinobacteria have historically provided many of these natural product compounds, but the
difficulty lies within coaxing the bacteria to produce. Genomic studies have found that numerous
well-characterized Actinobacteria still have cryptic secondary metabolite biosynthesis pathways
that are not expressed. Using our DNA methyltransferase inhibitor, we plan to disrupt gene
regulation of our Actinobacteria strain collection one by one and compare the secondary
metabolite crude extract of the modified and unmodified organisms. This comparison will allow
us to determine if cryptic secondary metabolite biosynthesis pathways have been unlocked, or
remain dormant.

We will first establish isolation protocols for growth of Actinobacteria from environmental
samples as well as identification techniques. After establishing an Actinobacteria strain
collection we will optimize methods of secondary metabolite extraction. Epigenetic modification
techniques will be optimized as well, which will determine the best parameters for inhibition of
DNA methylation including concentration of inhibitors, length of time for fermentation and what
media should be used. In order to determine if any of these secondary metabolites are effective
inhibitory agents, they will be screened against the multidrug resistant ESKAPE pathogens.
When a crude extract displays bioactivity above a specific threshold, it becomes viable for large25

scale

fermentation

and

purification.

Using

techniques

such

as

high-pressure

liquid

chromatography (HPLC), liquid chromatography coupled mass spectrometry (LC/MS), H1, C13,
COSY, and HSQC NMR we can elucidate the structure of a bioactive compound. We hope to
identify novel secondary metabolites that possess inhibitory activity against one or more of the
ESKAPE pathogens. It is possible a secondary metabolite of this nature could lead to
identification of a novel therapeutic that would aid in the war against multidrug resistant
pathogens.
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Materials and Methods

Initial Soil Collection and Processing Optimization
Two soil samples were collected from a farm in Ft. Meyers in May of 2015. The samples were
collected in sterile 50mL conical tubes from a depth of at least 15 cm. All future soil samples
were collected in the same fashion.

Media
All media were prepared by using deionized water supplemented with 36 g L-1 Instant Ocean®
and autoclaved for sterility. Media used for isolation and cultivation of Actinobacteria were
supplemented with antibiotics designated for inhibition of fungal cultures. The antibiotics were
added at the following concentrations: 50 µg mL-1 nystatin and 50 µg mL-1 cycloheximide.

Arginine-Glycerol-Salt Medium (AGS) (118)
0.1% Arginine monochloride

1 g L-1

1.25% Glycerol

12.5 g L-1

0.1% Dibasic potassium phosphate

1 g L-1

1.5% Agar

15 g L-1

Starch Casein Agar (SCA) (119)
0.1% Casein

1 g L-1

1.0% Soluble starch

10 g L-1

0.2% Potassium nitrate (KNO3)

2 g L-1
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15 g L-1

1.5% Agar

Salt-water Yeast Extract Agar (SYE)(120)
0.025% Yeast extract

0.25 g L-1

0.05% Dibasic potassium phosphate (K2HPO4)

0.5 g L-1

1.8% Agar

18 g L-1

International Streptomyces Project Medium – 2 (ISP-2)(120)
1.0% Malt extract

10 g L-1

0.4% Glucose

4 g L-1

0.4% Yeast extract

4 g L-1

1.5% Agar

15 g L-1

Tryptic Soy Broth (TSB)
30 g L-1

3.0% Tryptic soy

Inoculation Techniques
Method 1 (dilute/heat). One gram of soil samples was added to 5 mL of sterile seawater and
shaken vigorously until homogenized. Dilutions of the suspension were made to 10-3. The
dilution was heated to 55 °C for six minutes, then 100 µl were inoculated onto a sterile agar
plate and spread via autoclave sterilized glass beads (121).

Method 2 (dry/stamp). One gram of soil samples was added to a petri dish and allowed to dry
overnight in a laminar flow hood. Using a 2cm foam stamp, sample was stamped six to eight
times around the inside perimeter of the plate to simulate serial dilutions (121).
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Method 3 (dilute/spread). One gram of soil samples was added to 5 mL of sterile seawater and
shaken vigorously until homogenized. The homogenized mixture was then centrifuged 10
minutes at 2900 × g. Dilutions of the supernatant were made to 10-3. 100 µl were inoculated
onto a sterile agar plate and spread via autoclave sterilized glass beads (121).

Method 4 (dry/spread). One gram of soil samples was added to a petri dish and allowed to dry
overnight in a laminar flow hood. Dry sample was aseptically transferred directly to the agar
plate. The plate was flooded with 100 microliters of sterile seawater and spread via autoclave
sterilized glass beads (121).

Isolation and Purification of species
Plates were allowed to grow for 2-8 weeks and monitored weekly for growth. After plates
demonstrated growth, individual colonies were transferred to petri dishes containing ISP-2 for
isolation. Bacteria on plates of ISP-2 were streaked for isolation no fewer than three times to
ensure growth was identical to previous growth and isolation had been achieved.

DNA Extraction – Isolated colonies were grown in six mL of tryptic soy broth (TSB) for 3-7 days
at 28 °C in a shaking incubator until adequate growth was present to perform a DNA extraction
following manufacturer instructions (DNeasy Blood & tissue kit, Qiagen).

PCR Amplification – The 16S rRNA gene was then PCR amplified using the universal 16S rRNA
primer pair OL2629 (5’-CCA TCT CAT CCC TGC GTG TCT CCG ACT CAG TCT AAC GGA
CGA TAG AGT TTG ATC CTG GCT CAG-3’) (forward) and OL399 (5’-GGA CTA CCA GGG
TAT CTA ATC CTG TT-3’) (reverse) (122) and the products were purified using QIAquick PCR
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purification Kit (Qiagen) following the manufacturer instructions. Sanger sequencing based upon
OL2629 was performed and sequences generated were aligned and related to sequences
obtained from a NCBI Nucleotide BLAST (BLASTN) search in order to determine identity to at
least a genus level or if possible, a species level.

Current Actinobacteria Culture Techniques
Modified ISP-2 (120, 123, 124)
1.0% Malt extract

10 g L-1

0.4% Glucose

4 g L-1

0.4% Yeast extract

4 g L-1

1.5% Agar

15 g L-1

0.038% Tyrosine

0.38 g L-1

Isolate Identification
Inoculated agar plates were allowed to incubate for 2-8 weeks at room temperature to allow
slow-growing bacteria to form adequate sized colonies. Plates were monitored on a weekly
basis and adequate growth was monitored visually. Actinobacteria were removed from the low
nutrient media after no longer than 8 weeks of incubation based upon colony morphology, visual
confirmation of aerial mycelia or substrate hyphae, visual confirmation of spore formation,
pigment formation, or the presence of diffusible pigments. Colonies were separated and plated
on ISP-2 followed by serial streaking until isolation was achieved. ISP-2 supplemented with
tyrosine aided in further characterizing Actinobacteria, as there are numerous genera that are
able to produce the soluble pigment melanin. Isolates were then Gram-stained, in an effort to
eliminate the possibility of further characterization of Gram-negatives. Isolates were then DNA
extracted, the 16S rRNA gene was amplified via PCR for Sanger sequencing, followed by
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comparison of the generated sequences to known 16S rRNA genes using BLASTN. Isolates
that identified as Actinobacteria were added to the Shaw lab strain collection and frozen glycerol
stocks were prepared.

Isolates Used for Optimization Techniques
Cultures selected for epigenetic modification optimization were chosen for their phenotypic traits
as well as their unique metabolism and metabolites. Isolate 11 (Gordonia namibiensis) colonies
were slimy, smooth, orange in the center and white on the rim, and pinpoint. Isolate 11 was
chosen because Gordonia species have been found to possess unique metabolism, which
allows them to play a role in biodegradation of rubber materials, utilization of hydrocarbons, as
well as break down other natural products that are not easily degraded in the environment (125127). Isolate 39 (Streptomyces griseorubens) colonies were leathery, smooth, yellow, and
pinpoint that produced the soluble pigment melanin when plated on tyrosine containing media.
Isolate 39 was chosen because Streptomycetes are well known producers of bioactive
secondary metabolites and Streptomyces griseorubens has been noted for its ability to utilize
lignocellulose as its sole carbon source (128). Isolate 40 (Streptomyces fradiae) colonies were
leathery, smooth, white to yellow, pinpoint to large, and irregular. Isolate 40 was chosen also
because of Streptomycetes well known nature to produce bioactive secondary metabolites as
well as the bacterium’s ability to produce a number of well characterized compounds such as
neomycin, tylosin and urdamycins A-F (129-131). All three isolates were grown for 21 days in
ISP-2 broth (liquid media recipes omitted agar from preparation) prior to commencement of the
extraction methods below and performed in triplicate.
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Secondary Metabolite Extraction Optimization
Method A (partition/extract). Whole bacterial cultures were transferred from 50 mL bio-reactor
conical tubes to 120 mL glass French square bottles and partitioned using 25 mL of EtOAc.
Culture and organic layer were homogenized followed by transfer of the organic layer to preweighed 20 mL scintillation vials. Organic layer was dried under constant airflow. The addition of
EtOAc and transfer of the organic layer was repeated three times in order to obtain as much
product as possible.

Method B (freeze dry/extract). Whole bacterial cultures were frozen at -80°C and then
lyophilized. Dried material was then extracted using 25 mL of EtOAc. Whole extract was filtered
such that only EtOAc-soluble material could be transferred to pre-weighed 20 mL scintillation
vials. EtOAc was dried under constant airflow. The addition of EtOAc and whole extract filtration
was performed three times in order to obtain as much product as possible.

Method C (centrifuge/extract supernatant). Whole bacterial cultures were centrifuged and the
supernatant transferred to 120 mL glass French square bottles and partitioned using 25 mL of
EtOAc. Supernatant and organic layer were homogenized followed by transfer of the organic
layer to pre-weighed 20 mL scintillation vials. Organic layer was dried under constant airflow.
The addition of EtOAc and transfer of the organic layer was repeated three times in order to
obtain as much product as possible.

Method D (centrifuge/extract pellet). Whole bacteria cultures were centrifuged and the removed.
The pellet was frozen at -80°C and then lyophilized. Dried material was then extracted using 25
mL of EtOAc. Whole extract was then filtered such that only EtOAc-soluble material could be
transferred to pre-weighed 20 mL scintillation vials. EtOAc was dried under constant airflow.
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The addition of EtOAc and whole extract filtration was repeated three times in order to obtain as
much product as possible.

Epigenetic Modification Optimization
DNMTi Concentration Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2
media for three days in order to obtain a working stock. Each isolate was inoculated into 50 mL
bio-reactor conical tubes containing 35 mL of liquid media. The liquid media used for this
optimization was ISP-2 broth. 5-azacytidine was added to each of the flasks at the following
concentrations: 0 µM, 1 µM, 10 µM, 50 µM, 100 µM, and 500 µM. Tubes were allowed to
incubate for 21 days and were monitored for growth and color changes daily. A second round of
DNMTi concentration optimization was performed in conjunction with time optimization.

Time Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2 media for three
days in order to obtain a working stock. Each isolate was inoculated into 50 mL bio-reactor
conical tubes containing 35 mL of ISP-2 broth. 5-azacytidine was added to each of the 50 mL
bio-reactor conical tubes at the following concentrations: 0 µM, 1 µM, 5 µM, and 10 µM. Tubes
were allowed to incubate for 7, 14, and 21 days.

Media Optimization - Cultures of isolates 11, 39 and 40 were grown on ISP-2 media for three
days in order to obtain a working stock. Each isolate was inoculated into 50 mL bio-reactor
conical tubes containing 35 mL of SCA broth, SYE broth or ISP-2 broth. 5-azacytidine was
added to each of the 50 mL bio-reactor conical tubes at the following concentrations: 0 µM, 1
µM, and 5 µM. Tubes were allowed to incubate for 21 days.
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Screening Extracts Against the ESKAPE Pathogens
20 mL scintillation vials containing crude extract from the various extraction methods were resuspended in DMSO to a concentration of 5 mg mL-1. The extracts were assessed for the ability
to inhibit growth against the ESKAPE pathogens. ESKAPE pathogen strains were grown
overnight in TSB at 37 °C in a shaking incubator then diluted (10-3) into fresh media. The MIC
was determined through a tiered approach beginning with 200 µg mL-1 and continually halving
the inhibitory concentration until inhibition was no longer seen. Sterile 96-well microtiter plates
were loaded with culture and solvated compounds were added such that the total volume was
200 µl.

Small-Scale Growth
Slow growing Actinobacteria were grown at 28 °C in 35 mL of SCA broth in 50 mL bio-reaction
conical tubes (Cell-Treat) in a shaking incubator under constant agitation for 21 days, in the
presence and absence of one µM of our DNMTi (5-azacytidine). Rapidly growing Actinobacteria
were also grown at 28 °C in 35 mL of ISP-2 broth in 50 mL bio-reaction conical tubes (CellTreat) in a shaking incubator under constant agitation for 21 days, in the presence and absence
of one µM of 5-azacytidine. The bio-reaction conical tubes were monitored for color changes
and secreted pigments throughout the incubation period.

Secondary Metabolite Extraction – after 21 days of growth, actinobacterial cultures were
transferred to 120 mL glass French square bottles and 25 mL of ethyl acetate (EtOAc) were
added to the glass bottles, the culture/EtOAc mixture was homogenized and filtered. The
resulting mixture was allowed to settle for 24 hours and layers were formed, after which the top
organic layer was decanted into a pre-weighed 20 mL scintillation vial. Care was taken to
ensure only the EtOAc layer was removed and not the aqueous layer containing the media and
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bacterial cultures. This process was repeated three times in order to remove as much material
potentially containing secondary metabolites as possible. Between removals of the organic
layers, the previously removed EtOAc was dried; secondary and tertiary removals of EtOAc
were added to the same corresponding scintillation vials. Scintillation vials were weighed after
drying to determine total yield of crude extract. Crude extracts weighing >= 1 mg were solvated
to 5 mg mL-1 in 100% dimethyl sulfoxide (100% DMSO), 0.5 – 0.99 mg were solvated to 2.5 mg
mL-1 in 100% DMSO, and <0.5 mg were solvated to 1 mg mL-1 in 100% DMSO. Aliquots of
extracts were transferred into 96-well plates, with stock solutions archived.

ESKAPE Bioactivity Screening – in order to assess the antimicrobial activity of the crude
extracts we used the ESKAPE pathogens, which are an excellent representation for multidrug
resistant pathogens. All of the ESKAPE strains were grown overnight in TSB at 37 °C in a
shaking incubator, and then diluted (10-3) into fresh media. The minimum inhibitory
concentration (MIC) was determined through a tiered approach beginning with 200 µg mL-1 and
continually halving the inhibitory concentration until inhibition was no longer seen. Sterile 96-well
microtiter plates were loaded with culture, and solvated compounds were added to equal a total
volume of 200 µl. Care was taken not to add more than 5% of the total volume of the compound
to any of the wells and a control well was included with 5% total volume being 100% DMSO.
Plates were then incubated at 37°C for 24 hours and MICs were determined via visual
inspection, inhibition was apparent by a lack of turbidity in the wells.

Large-Scale Growth
Actinobacteria were grown in 1000 mL of SCA broth at 28 °C in a two liter Erlenmeyer flask in a
shaking incubator under constant agitation for 28 days. The flasks were monitored for color
changes and secreted pigments throughout the incubation period. After 28 days of growth 500
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mL of EtOAc were added to the flask and the culture/EtOAc mixture was homogenized by
shaking incubator for 24 hours. The resulting mixture was filtered and allowed to settle for 24
hours before decanting the organic layer. This process was repeated twice more using only 250
mL of EtOAc in order to remove as much material potentially containing secondary metabolites
as possible. Between removals of the organic layers, the previously removed EtOAc was dried;
secondary and tertiary removals of EtOAc were added to the same corresponding glass bottle.
Five milligrams of crude extract was removed and placed in a 20 mL scintillation vial and kept
for storage.

Partition – The whole crude extract was suspended in EtOAc and transferred to a separatory
funnel and partitioned using double distilled H2O. Three partitions were collected in separate
20mL scintillation vials, the liquid layer (H2O), the middle layer (insoluble material) and the
organic layer (EtOAc). These partitions were dried under air and weighed, then five milligrams
of each were removed and placed in separate 20 mL scintillation vials and kept for storage.
Following the partition, whole crude extract, as well as each of the partitions were subjected to
bioassay to ensure activity of the large-scale extract and partitions were similar to that of the
small-scale crude extract as well as determine the active partition for further characterization
and testing.

HPLC Purification and Bioassay Guided Fractionation
The

bioactive

crude

extract

was

subjected

to

normal-phase

high-pressure

liquid

chromatography (HPLC) purification with two silica columns in tandem as the stationary phase.
The mobile phase used a five minute 100% hexanes run, followed by a 35-minute continuous
gradient until 100% EtOAc, then a 15-minute 100% EtOAc run, and finally a 10-minute 100%
50:50 EtOAc:IPA wash. An evaporative light scattering (ELS) as well as an ultraviolet (UV)
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detector monitored HPLC analysis in order to identify a variety of potential fractions. Fractions
were submitted to bioassay to determine which possessed the activity seen in the crude extract.

Modified HPLC Purification and Bioassay Guided Fractionation
Partitioned crude extracts were used as an initial modification of this purification process. The
bioactive partition was subjected to normal-phase HPLC purification with a silica stationary
phase. The mobile phase used a five minute 100% hexanes run, followed by a 35-minute
continuous gradient until 100% 50:50 EtOAc:IPA, then a 15 minute 100% 50:50 EtOAc:IPA run.
An evaporative light scattering (ELS) as well as an ultraviolet (UV) detector monitored HPLC
analysis in order to identify a variety of potential fractions. Fractions were submitted to bioassay
to determine which possessed the activity seen in the active partition.

Bioactive fractions were subjected to reverse-phase HPLC purification with a C8 column, using
a five minute 90% H2O: 10% 1:4 THF:ACN run, followed by a 35 minute continuous gradient
until 99% 1:4 THF:ACN, then a 15 minute 1% H2O 99% 1:4 THF:ACN run. and this process will
be repeated until a single bioactive compound has been identified. Purified bioactive fractions
will be analyzed by liquid chromatography coupled mass spectrometry (LCMS) in order to
identify

a

molecular

weight

and
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potential

chemical

formula.

Results

Investigating Cultivation Strategies Necessary for Actinobacteria Growth
Historically, Actinobacteria have been an ample source of antibiotics and bioactive secondary
metabolites, the difficulty lying within the recovery rate of isolates from environmental samples.
Initially, using the two soil samples from the farm in Ft. Meyers, we attempted to isolate and
identify Actinobacteria. Using SCA, SYE, and AGS coupled with methods 1-4 and performing
each combination in triplicate, we generated 36 plates per sample. After eight weeks of growth,
we began serially streaking isolates onto ISP-2 agar plates to ensure isolation. A total of 432
isolates were obtained from the investigation of cultivation strategies (Table 1). We selected 36
isolates that possessed at least one of the Actinobacteria-like characteristics including rough or
leathery colonies, aerial hyphae, substrate mycelia, presence of pigments, presence of spores,
or diffusible pigments to perform Sanger sequencing. Media or methods that were considered
optimal and use continued resulted in Actinobacteria identification for at least 80% of the
sequenced isolates from their respective media or method (Table 2). The various identified
isolates were from both samples, Soil 1 and Soil 2, and both samples possessed identified
Actinobacteria. Isolates identified as Actinobacteria included species from the genera
Rhodococcus,

Streptomyces,

Gordonia,

Nocardia,

Arthrobacter,

Aeromicrobium,

and

Mycobacterium (Table 3). These preliminary results demonstrate the omnipresence of
Actinobacteria. Using this preliminary data, we were able to determine that SCA and SYE in
conjunction with methods one and three were optimal for growth and isolation of Actinobacteria
and were used moving forward with future soil samples.
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Table 1. Number of Isolates Obtained Using Various Media and Methods

Method
1

Media
AGS
SYE

Number of Isolates from Soil 1
23
29

Number of Isolates from Soil 2
41
63

2

SCA
AGS
SYE

25
5
13

37
13
10

3

SCA
AGS
SYE

4
14
18

15
28
16

4

SCA
AGS
SYE

19
4
8

11
16
6

SCA
7
7
Total isolates
169
263
* Listed are the total yields from each media and method combination from environmental
samples Soil 1 and Soil 2. Media used includes: AGS – arginine-glycerol-salt; SYE – salt-water
yeast-extract; SCA – starch casein agar.

Table 2. Prevalence of Actinobacteria

Media
AGS
SCA
SYE

Percent Actinobacteria
22%
95%
80%

Method
1
2
3

Percent Actinobacteria
84%
43%
80%

4

0%

* Listed are the percentages associated with the number of Actinobacteria identified that were
cultivated under each media type or method. Media used includes: AGS – arginine-glycerol-salt;
SYE – salt-water yeast-extract; SCA – starch casein agar
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Table 3. Identity and Acquisition Method
Strain Number
Identity
Media
Method
Sample
1
Rhodococcus rhodochrous
SCA
3
Soil 2
2
Staphylococcus gallinarum
SYE
3
Soil 2
3
Staphylococcus cohnii
AGS
3
Soil 2
4
Bacillus aryabhattai
AGS
2
Soil 2
5
Rhodococcus rhodochrous
SCA
1
Soil 2
6
Streptomyces violarus
SCA
3
Soil 1
7
Streptomyces sp.
SCA
1
Soil 2
8
Streptomyces beijiangensis
AGS
1
Soil 2
9
Halomonas venusta
AGS
1
Soil 2
10
Streptomyces coelicoflavus
SCA
1
Soil 2
11
Gordonia namibiensis
SCA
1
Soil 2
12
Rhodococcus rhodochrous
SCA
1
Soil 2
13
Nocardia vermiculata
SCA
1
Soil 2
14
Streptomyces platensis
SCA
1
Soil 1
15
Streptomyces violarus
SCA
1
Soil 2
16
Streptomyces albiflavescens
SCA
1
Soil 2
17
Streptomyces corchorusii
SCA
1
Soil 2
18
Arthrobacter protophormiae
SYE
1
Soil 2
19
Gordonia namibiensis
SCA
3
Soil 1
20
Aeromicrobium tamlense
SCA
2
Soil 2
21
Rhodococcus phenolicus
SCA
2
Soil 2
22
Gordonia terrae
SCA
3
Soil 1
23
Bacillus sp.
AGS
2
Soil 2
24
Bacillus sp.
AGS
2
Soil 2
25
Rhodococcus rhodochrous
SCA
2
Soil 2
26
Streptomyces chromofuscus
SCA
1
Soil 2
27
Streptomyces acrimycini
SCA
1
Soil 2
28
Bacillus aryabhattai
AGS
2
Soil 2
29
Mycobacterium parafortuitum
SCA
3
Soil 2
30
Streptomyces macrosporeus
SCA
3
Soil 2
31
Streptomyces antibioticus
SYE
3
Soil 1
32
Streptomyces gardneri
SCA
3
Soil 1
33
Streptomyces tumescens
AGS
1
Soil 1
34
Nocardia asteroides
AGS
1
Soil 1
35
Streptomyces minoensis
SYE
1
Soil 1
36
Streptomyces aurantiogriseus
SYE
1
Soil 2
* Listed are the strain numbers used as an identifier for each addition to the Actinobacteria
strain collection as well as the respective isolate identity, media, method, and environmental
sample used for cultivation. Media used includes: AGS – arginine-glycerol-salt; SYE – salt-water
yeast-extract; SCA – starch casein agar.
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Using SCA and SYE with methods one and three, and plating in triplicate, a total of 12 plates
were generated per sample in order to accurately cultivate potential microbes harbored within
the environmental samples. Environmental samples were acquired from a variety of sources
including farmland, deserts, aquatic environments, as well as high altitudes (Table 4).

Model for Rapid Identification of Actinobacterial Cultures and Strain Collection
Development
Typically, the identification of an unknown bacterium can be determined using 16S rRNA gene
sequencing, which can be compared to previously sequenced genes, to provide an identity to a
genus and sometimes species level. A common issue within the phylum is the similarity of the
16S rRNA gene sequence, which raises difficulties when organizing isolates at a species level.
This common issue has limited our identification to at least a genus level, and in some cases a
species level identification was achieved when comparable genetic sequences were available.
A number of modifications were made when transitioning between investigating cultivation
strategies and current cultivation strategies, which include added steps to rapidly detect
Actinobacteria, thereby reducing costs associated with identification via Sanger sequencing.
Recognizing that a number of bacteria possess tyrosinases, which can be used in the formation
of pigments such as melanin, was a crucial step in the rapid identification of Actinobacteria
(124). As one of the Actinobacteria-like indicators was pigment production, the addition of
tyrosine to our ISP-2 media aided immensely. The production of melanin was added to the list of
Actinobacteria-like indicators. Many of the colonies cultivated from environmental samples
possessed at least one of the Actinobacteria-like indicators, such that upon visual inspection, a
colony could be identified as Actinobacteria-like or not. This visual identification made it possible
to remove the need for Sanger sequencing of each isolate. 16S rRNA gene sequencing was still
of use for isolates that did not possess at least one of the Actinobacteria-like indicators.
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Table 4. List of Environmental Samples
Sample
Number
-3
-2
-1
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Location

Description

Soil 1
Soil 2
Sed 8
Sed 10
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
TSF
SHH
SHH
SIS
SIS
SIS
SHH
CWR
CWR
CWR
CWR
CWR
CWR
CWR
CWR
CWR
CWR
CWR

Farm (field) Ft. Myers
Farm (horse) Ft. Myers
Florida Keys
Florida Keys
Oak hickory heavy shade
Cow loading area, empty for years
Cow pasture, under hay (feeding area)
Pond 1 edge
Pond 1 edge further out
Pond 2 edge
Arid cow pasture
Organic soil, heavy trees
low lands (wet cow pasture)
Organic soil, cedar trees
Gopher hole
Forest Floor
Deep in the forest
Deeper in the forest
Cave floor
Clay near house
Deep under sprinkler
Front Garden
Ding Darling Island
Beach Dunes
Low tide beach
Back garden
14
15-16
15-18
15-19
15-20
15-21
15-22
15-23
15-SED1
15-SED2
15-SED3
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Type of
Sample
Soil
Soil
Sediment
Sediment
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sediment
Sediment
Sediment

Number of
Isolates
32
119
N/A
N/A
36
30
48
32
16
13
29
1
31
69
8
14
5
10
17
1
10
60
66
84
N/A
N/A
1
N/A
N/A
N/A
1
N/A
N/A
N/A
1
N/A
N/A

Table 4. (Continued)
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71

BB
BB
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15
MFG15

15-6
15-3
Sed 1
Sed 2
Sed 3
Sed 4
Sed 5
Sed 6
Sed 7
Sed 8
Sed 9
Sed 10
Sed 11
Sed 12
Sed 13
Sed 14
Sed 15
Sed 16
Sed 17
Sed 18
6a
6b
8
10
12
14
16a
16b
18
20
22
24
26
30
32
38
40
42
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Soil
Soil
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sediment
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge
Sponge

N/A
8
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Table 4. (Continued)
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103

MFG15
MFG15
MFG15
MFG15
EG 15
EG 15
EG 15
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
HRT
TN16
TN16
TN16
TN16
TN16
TN16
TN16
TN16
TN16
TN16
TN16
TN16

104
105
106
107
108
109

TN16
RC16
AS16
AS16
AS16
AS16

52
54
56
60
Sand 1
Sand 2
Sahel shemally
Memphis, TN
Newalla, OK
Muldrow, OK
South Rim Grand Canyon, AZ
Hatch, UT
Death Valley Lakebed
Amarillo, TX
Fulton, MS
Brinkley, AR
Moriarty, NM
Chambers, AZ
Lone Pine, CA
Valley of Fire, NV
Tri-cities, TN beside boulder
Tri-cities, TN rattlesnake trail
Tri-cities, TN tree roots
Tri-cities, TN under tree
Tri-cities, TN on Embankment
Church Hill, TN (1509 ft.)
Church Hill, TN (1445 ft.)
Johnson City, TN (1481 ft.)(soil in root)
Church Hill, TN (1466 ft.)
Church Hill, TN (1394 ft.) (bottom layer)
Johnson City, TN (1481 ft.)(under wagon)
Church Hill, TN (1396 ft.) (top layer)
Johnson City, TN (1481 ft.) (soil below
root)
Shamrock Soil
Forrest in Newton, PA (#1)
Forrest in Newton, PA (#2)
Forrest in Newton, PA (#3)
Forrest in Newton, PA (#4)
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Sponge
Sponge
Sponge
Sponge
Sand
Sand
Sediment
Soil
Soil
Soil
Sand
Soil
Sand
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil
Soil

N/A
N/A
N/A
N/A
10
9
N/A
3
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Soil
Soil
Soil
Soil
Soil
Soil

N/A
N/A
N/A
N/A
N/A
N/A

Table 4. (Continued)
110
WR16
11,753 ft., Estes Park, CO
Soil
N/A
111
WR16
12,193 ft., Estes Park, CO
Soil
N/A
112
WR16
9,247 ft., Estes Park, CO
Soil
N/A
113
WR16
9,444 ft., Estes Park, CO
Soil
N/A
114
WR16
10,057 ft., Estes Park, CO
Soil
N/A
115
NV16
Nashville, TN 795 ft.
Soil
N/A
116
NV16
Nashville, TN Valve House Trail
Soil
N/A
117
PH16
USF campus, FL
Soil
N/A
118
PH16
Tampa, FL
Soil
N/A
119
PH16
Tampa, FL
Soil
N/A
120
PH16
Tampa, FL
Soil
N/A
121
PH16
Tampa, FL
Soil
N/A
122
PH16
Tampa, FL
Soil
N/A
* Listed are the environmental samples acquired throughout this study as well as the associated
number of Actinobacteria identified. Location identifiers are: TSF – Te Strake farm; SHH –
Shaw House; SIS – Sanibel Island soil; CWR – Clearwater reef; BB – Bill Baker; MFG15 –
Florida middle grounds 2015; EG 15 – Egypt 2015; HRT – Hailey road trip; TN16 – Tennessee
2016; RC16 – Ronan Carroll 2016; AS16 – Arielle Sharp 2016; WR16 – Wind river 2016; NV16
– Nashville, Tennessee 2016; PH16 – Phage biology class 2016.
* N/A indicates samples have not yet been processed.
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Over 750 isolates displaying Actinobacteria-like indicators have been added to the Shaw lab
Actinobacteria strain collection, of which over 200 have a confirmed genus based upon BLASTN
confirmation of the 16S rRNA gene (Appendix I). The over 200 Actinobacteria are represented
a variety of genera, including, Aeromicrobium, Agromyces, Arthrobacter, Brevibacterium,
Gordonia,

Isoptericola,

Micromonospora,

Leifsonia,

Nocardia,

Microbacterium,

Nocardioides,

Micrococcus,

Promicromonospora,

Mycobacterium,
Pseudonocardia,

Rhodococcus, Streptomyces, and Williamsia (Table 5). The most abundant of the genera,
Streptomyces, which comprises more than half of the identified isolates, originated from all
sample sites screened for Actinobacteria. This finding is concurrent with the literature that
suggests that majority of the Actinobacteria found within the soil are of the genus Streptomyces
(68). A circular cladogram was constructed with the over 200-actinobacterial-16S rRNA genes
that displays the vast diversity of our collection as well as separates the genera into their
respective families and orders (Figure 6). All Sanger sequenced isolates belong to the same
class, Actinobacteria.
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Table 5. Order, Family and Genus of Identified Isolates
No. of isolates
1
2
2
1
6
1
3
3
2
20
1
9
2
1
1
20
163

Genus
Aeromicrobium
Agromyces
Arthrobacter
Brevibacterium
Gordonia
Isoptericola
Leifsonia
Microbacterium
Micrococcus
Mycobacterium
Micromonospora
Nocardia
Nocardioides
Promicromonospora
Pseudonocardia
Rhodococcus
Streptomyces

Family
Nocardioidaceae
Microbacteriaceae
Micrococcaceae
Brevibacteriaceae
Nocardiaceae
Promicromonosporaceae
Microbacteriaceae
Microbacteriaceae
Micrococcaceae
Mycobacteriaceae
Micromonosporaceae
Nocardiaceae
Nocardioidaceae
Promicromonosporaceae
Pseudonocardiaceae
Nocardiaceae
Streptomycetaceae

Order
Proprionibacteriales
Micrococcales
Micrococcales
Micrococcales
Corynebacteriales
Micrococcales
Micrococcales
Micrococcales
Micrococcales
Corynebacteriales
Micromonosporales
Corynebacteriales
Proprionibacteriales
Micrococcales
Pseudonocardiales
Corynebacteriales
Streptomycetales

1
Williamsia
Nocardiaceae
Corynebacteriales
* Listed are the different genera identified throughout this study as well as their respective
family, order, and the number of isolates obtained that belongs to each genus.
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Figure 6. Circular Cladogram of Identified Actinobacteria
Cladogram was assembled using the 16S rRNA gene from identified Actinobacteria within our
strain collection. Colors surrounding the cladogram identify bacteria as displaying specific traits
or production of known compounds.
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Secondary Metabolite Extraction Optimization
Secondary metabolite extraction results in a crude extract that may contain thousands of
compounds, some of which may polar, non-polar, insoluble, temperature sensitive, pH sensitive,
or even sensitive to the type of solvent used. As a consequence of the number of variables we
strove to identify a method for secondary metabolite extraction that would afford suitable
weights with which to work in a high throughput fashion. All three isolates (11, 39 and 40) were
grown in triplicate for a period of 21 days and each were extracted following each of the
methods above (A-D). The crude extract weights were recorded and used to determine which of
the extraction methods would work best in a high throughput manner (Table 6). It was
determined based upon average weights of all three isolates for each of the extraction methods
that extraction method B would work optimally.

Epigenetic Modification Optimization
DNMTi Concentration Optimization – It was not yet known how 5-azacytidine would interact with
our three isolates or the necessary concentration to use that would confer a change. Based
upon existing literature for epigenetically modified fungi, we decided it would be best to optimize
this method to ensure appropriate concentrations were being tested. Initial concentrations of 5azacytidine included: 0 µM, 1 µM, 10 µM, 50 µM, 100 µM, and 500 µM. Eighteen 50 mL
bioreactor conical tubes were used to determine the maximum threshold for unaltered growth of
each of the Actinobacteria. All three isolates had no visually noticeable growth defects at 0 µM
and 1 µM concentrations. All three isolates showed some visually noticeable growth defects at
the 10 µM concentration. None of the isolates matured passed inoculation in any of the
concentrations greater than 10 µM (Table 7).
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Extraction
Isolate 11 (milligrams)
Average
Isolate 39 (milligrams)
Average
Isolate 40 (milligrams)
Average
Method
A
0.70
0.80
0.30
0.60
0.80
0.70
0.60
0.70
0.70
0.70
0.30
0.56
B
1.20
2.60
4.80
2.86
3.10
2.4
1.20
2.23
1.90
15.90
3.60
7.13
C
1.50
0.50
0.60
0.86
2.30
1.90
2.00
2.06
0.80
0.90
1.40
1.03
D
1.70
2.60
2.20
2.16
2.60
1.90
4.90
3.13
1.60
3.50
0.80
1.96
* Listed are the extraction methods used for extraction optimization; these were performed identically for each of the isolates. As
there was no uniformity throughout each of the extraction methods, averages were taken across the isolates as well as within the
isolates to determine which of the methods would be optimal for this high throughput screening campaign.

Table 6. Secondary Metabolite Extraction Results

Table 7. Growth Based Upon Concentration of DNMTi
[DNMTi]
Isolate 11
Isolate 39
Isolate 40
0 µM
Growth
Growth
Growth
1 µM
Growth
Growth
Growth
10 µM
Growth Defect
Growth Defect
Growth Defect
50 µM
No Growth
No Growth
No Growth
100 µM
No Growth
No Growth
No Growth
500 µM
No Growth
No Growth
No Growth
* Listed are the DNA methyltransferase inhibitor (DNMTi) concentrations used. Cultures were
assessed based upon growth or no growth. A culture was labeled with growth defect if the
culture did not achieve growth comparable to that of the control culture.
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Basing this initial optimization solely on visual inspection, it was determined that another round
of DNMTi concentration optimization would be performed following a more narrow scope of
concentrations.

Time Optimization – Majority of Actinobacteria possess doubling times significantly longer than
other bacteria, such as Staphylococcus aureus, which can have doubling times as low as 24
minutes under laboratory conditions (132). As such, we needed to optimize a length of time that
would suit majority of the Actinobacteria collection in a high throughput fashion. Cultures of
isolates 11, 39, and 40 represent varying growth rates, which can provide a length of time that
suits all isolates. In conjunction with time optimization, we also further specified the
concentration of our DNMTi. Each of the isolates were challenged with the following
concentrations of 5-azacytidine: 0 µM, 1 µM, 5 µM, and 10 µM. These tubes were allowed to
incubate for 7, 14, or 21 days in triplicate. At each of the time points, a tube with each of the
combinations of isolates and concentrations of 5-azacytidine were extracted with method B
mentioned above. The crude extract weights were measured at each of time points and
averaged (Table 8). All samples yielded, regardless of concentration of 5-azacytidine, the
highest mass after 21 days of incubation. While samples that were inoculated with 10 µM of 5azacytidine for 21 days averaged the highest mass overall, it was clear that majority of the
extracted mass was unusable and contained significant levels of cell material. These results
provided an optimal length of time for incubation of 21 days, but still did not provide an optimal
concentration of 5-azacytidine that would allow for continuous growth of the isolates. Therefore
yet another round of DNMTi concentration optimization would be performed following an even
more narrow scope of concentrations.
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Media Optimization – Numerous studies have been performed in the hopes of determining
optimal media for the production of antibiotics. A study by Cortes et al. found that in
Streptomyces too much glucose could inhibit antibiotic production as it signals to the bacteria
that there is an abundance of nutrients (133). Therefore it was essential to determine which of
the media (SYE broth, SCA broth or ISP-2 broth) would be optimal for growth and production of
secondary metabolites. In conjunction with media optimization, we further explored the optimal
concentration of 5-azacytidine to include the following concentrations: 0 µM, 1 µM, and 5 µM in
triplicate. With all three media options, a tube with each of the combinations of isolates and
concentrations of 5-azacytidine were extracted with method B after 21 days of growth. Averages
of the crude extract weights were taken for each of combinations and averaged (Table 9). All of
the sample’s averages yielded the highest crude extract mass in either the SCA and ISP-2
broths. The samples in all instances except one resulted in the highest crude extract mass in
either the unmodified or 1 µM concentration of 5-azacytidine. These results provided both the
optimal media for the production of secondary metabolites as well as the optimal concentration
of 5-azacytidine for modification of Actinobacteria isolates.

Before commencement of analysis of secondary metabolite production from our Actinobacteria
strain collection, we needed to optimize a number of factors. These results aided in identifying
the optimal parameters for the growth of these bacteria including two different media (SCA and
ISP-2), a time frame with which to grow each batch (21 days) and the appropriate concentration
of

5-azacytidine

to

use

in

conjunction
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with

an

unmodified

control

(1

µM).

7 Days
(milligrams)

7 Days
Average

14 Days
(milligrams)

14 Days
Average
21 Days (milligrams)

21 Days
Average
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Isolate 11
1.50 0.90
1.20
1.20
1.10 1.90
3.20
2.07
7.30 11.90 5.20
8.13
(0 µM)
Isolate 11
3.00 0.20
1.40
1.53
1.20 1.80
3.50
2.17
5.00 34.70 12.10
17.27
(1 µM)
Isolate 11
4.10 2.20
0.60
2.30
1.30 0.60
1.00
0.97
7.10
5.10 24.00
12.07
(5 µM)
Isolate 11
2.20 1.40
0.20
1.27
0.00 0.70
0.50
0.40
6.30 12.00 32.90
17.07
(10 µM)
Isolate 39
0.60 1.40
1.30
1.10
0.30 1.20
2.80
1.43
9.80
8.80
2.30
6.97
(0 µM)
Isolate 39
9.90 8.00
2.40
6.77
0.80 0.60
0.00
0.47
24.60 30.40 0.40
18.47
(1 µM)
Isolate 39
5.70 21.10 2.90
9.90
0.30 0.30
0.40
0.33
55.20 14.20 29.40
32.93
(5 µM)
Isolate 39
0.20 0.00
0.00
0.07
2.40 3.20
1.20
2.27
4.50 14.70 1.10
6.77
(10 µM)
Isolate 40
7.20 0.50
0.20
2.63
0.70 0.20
0.70
0.53
0.70 40.00 14.70
18.47
(0 µM)
Isolate 40
2.00 4.80
1.20
2.67
0.50 2.80
2.40
1.90
21.30 1.00
3.30
8.53
(1 µM)
Isolate 40
1.80 1.20
0.70
1.23
0.60 0.50
0.90
0.67
45.60 0.20
4.10
16.63
(5 µM)
Isolate 40
3.60 3.00
0.40
2.33
0.30 4.70 17.30
7.43
65.50 33.70 16.40
38.53
(10 µM)
* Listed are the concentrations of DNA methyltransferase inhibitor (DNMTi) used as well as the different lengths of time for
optimization of cultivation period. In all cases, after 21 days of growth yielded the highest mass average.

Concentration

Table 8. Length of Time for Cultivation and DNMTi Concentration Results

0.40

0.60

0.10

0.10

0.70

1.40

0.10

0.70

0.70

0.50

0.10

0.10

0.10

3.60

1.40

0.10

0.20

1.10

0.40

0.10

0.50

2.30

1.40

1.20

SYE Broth
(milligrams)

0.43

0.73

0.20

0.10

0.43

2.43

0.97

0.67

SYE Broth
Average

0.10

0.50

0.30

0.10

0.10

1.10

4.90

0.70

1.90

6.20

0.10

0.10

0.20

0.10

1.50

1.00

1.60

0.20

0.20

0.50

0.10

0.10

1.60

10.00

SCA Broth
(milligrams)

1.20

2.30

0.20

0.23

0.13

0.43

2.67

3.90

SCA Broth
Average

2.70

0.90

0.10

1.00

1.00

0.20

0.60

0.30

0.70

0.10

0.70

0.80

1.90

0.40

0.30

1.20

1.00

0.50

0.50

0.70

1.00

1.00

0.90

0.30

ISP-2 Broth
(milligrams)

1.47

0.50

0.43

0.83

1.30

0.53

0.60

0.60

ISP-2 Broth
Average
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0.10 0.10 0.10
0.10
0.10 0.10
0.80
0.33
1.20 1.20 1.30
1.23
(5 µM)
* Listed are the concentrations of DNA methyltransferase inhibitor (DNMTi) used as well as the different media types for optimization.
Media used includes: SYE – salt-water yeast-extract; SCA – starch casein agar.

Isolate 40

(1 µM)

Isolate 40

(0 µM)

Isolate 40

(5 µM)

Isolate 39

(1 µM)

Isolate 39

(0 µM)

Isolate 39

(5 µM)

Isolate 11

(1 µM)

Isolate 11

(0 µM)

Isolate 11

Concentration

Table 9. Media and DNMTi Concentration Results

Quantitative Analysis of Secondary Metabolite Production of Actinobacteria Strain
Collection
Bacteria utilize DNA methylation as a method to rapidly activate or inactivate gene transcription,
which allows them to acclimate to their environment more efficiently (95). As such, using 5azacytidine to prevent DNA methylation has the potential to disrupt bacterial gene expression
including, but not limited to secondary metabolite biosynthesis pathways.

Secondary metabolites have the potential to affect a plethora of cellular functions including cell
wall development, protein synthesis, protein function and fatty acid synthesis/metabolism (77).
Therefore, using purified bacterial isolates from soil and sediment samples, a total of 148
bacterial isolates have been screened for the presence of bioactive secondary metabolites.
After 21 days of incubation in the presence and absence of 1 µM of 5-azacytidine, it was seen
that all of the Actinobacteria were able to produce some level of crude extract (Table 10). The
masses of crude extract from each of the bacterial isolates varied greatly, however, there were
40 of the 148 (27%) isolates that had >= +/- 1.0 mg difference between the challenged and
unchallenged samples. The remaining 108 (73%) varied between challenged and unchallenged
less than +/- 1.0 mg or there were no changes. The changes in crude extract mass observed in
the 40 isolates with >= +/- 1.0 mg indicates there may be a difference in regulation between the
two. The differences seen in crude extract weight may provide insight into how much material is
being produced, however there is no indication as to what is being produced and whether or not
bioactive secondary metabolite regulation is being disrupted.

Evaluating the Effects of Crude Secondary Metabolites Against the ESKAPE Pathogens
A major problem with the discovery of bioactive secondary metabolites lies within determination
of how to assess such activity and where to focus our efforts. A majority of compounds
56

Table 10. Comparison of Crude Extract Mass
Strain
Number
1
5
6
7
8
10
11
12
13
14
15
16
17
18
19
20
21
22
25
26
27
29
30
31
32
33
34
35
36
37
39
40
41
42
43
44
45

Identity
Rhodococcus rhodochrous
Rhodococcus rhodochrous
Streptomyces violarus
Streptomyces sp.
Streptomyces beijiangjensis
Streptomyces coelicoflavus
Gordonia namibiensis
Rhodococcus rhodochrous
Nocardia vermiculata
Streptomyces platensis
Streptomyces violarus
Streptomyces antibioticus
Streptomyces corchorusii
Arthrobacter protophormiae
Gordonia namibiensis
Aeromicrobium tamlense
Rhodococcus phenolicus
Gordonia terrae
Rhodococcus rhodochrous
Streptomyces chromofuscus
Streptomyces acrimycini
Mycobacterium parafortuitum
Streptomyces macrosporeus
Streptomyces antibioticus
Streptomyces gardneri
Streptomyces tumescens
Nocardia asteroides
Streptomyces minoensis
Streptomyces aurantiogriseus
Streptomyces matensis
Streptomyces griseorubens
Streptomyces fradiae
Streptomyces violascens
Streptomyces zaomyceticus
Streptomyces viridochromogenes
Streptomyces beijiangensis
Streptomyces intermedius

Unchallenged
(milligrams)
2.6
3.0
1.7
1.6
1.2
2.2
6.4
9.3
4.6
9.3
3.4
14.7
1.8
4.2
3.1
16.3
13.8
6.5
3.0
3.2
6.7
2.0
6.2
12.0
1.6
4.0
4.1
2.1
3.0
2.6
4.7
2.7
3.6
2.0
7.6
3.4
4.8
57

Challenged
(milligrams)
3.5
3.1
1.4
1.9
0.9
1.6
6.2
6.4
3.5
4.7
3.0
13.9
2.2
2.2
4.4
13.3
14.8
6.4
2.3
8.5
4.3
2.4
22.5
16.9
2.3
3.1
3.3
2.2
3.1
3.1
6.8
3.0
4.2
2.2
6.8
4.2
4.6

Change
(milligrams)
0.9
0.1
-0.3
0.3
-0.3
-0.6
-0.2
-2.9
-1.1
-4.6
-0.4
-0.8
0.4
-2.0
1.3
-3.0
1.0
-0.1
-0.7
5.3
-2.4
0.4
16.3
4.9
0.7
-0.9
-0.8
0.1
0.1
0.5
2.1
0.3
0.6
0.2
-0.8
0.8
-0.2

Table 10. (Continued)
46
47
48
49
50
51
52
54
56
57
58
59
60
61
62
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
84
85
86
87
88

Streptomyces intermedius
Streptomyces albidoflavus
Streptomyces matensis
Streptomyces griseoplanus
Streptomyces drozdowiczii
Streptomyces drozdowiczii
Streptomyces coelicoflavus
Streptomyces intermedius
Streptomyces intermedius
Streptomyces sampsonii
Nocardia asteroides
Nocardia asteroides
Streptomyces glebosus
Streptomyces hawaiiensis
Streptomyces variabilis
Streptomyces drozdowiczii
Streptomyces drozdowiczii
Streptomyces griseoaurantiacus
Streptomyces intermedius
Streptomyces thermocarboxydus
Streptomyces viridobrunneus
Streptomyces intermedius
Brevibacterium epidermidis
Streptomyces intermedius
Microbacterium ginsengterrae
Streptomyces coelicoflavus
Streptomyces gardneri
Streptomyces intermedius
Streptomyces malachitospinus
Streptomyces intermedius
Streptomyces aurantiacus
Streptomyces malachitospinus
Streptomyces tendae
Streptomyces drozdowiczii
Streptomyces tendae
Streptomyces tendae
Streptomyces gardneri
Streptomyces praecox
Streptomyces turgidiscabies

5.1
3.2
2.4
11.5
1.2
1.8
2.1
1.4
3.3
2.3
3.0
3.4
4.8
2.4
2.1
4.5
3.5
2.6
2.5
2.5
1.8
2.4
2.3
4.5
4.0
1.6
1.7
2.5
1.6
2.9
3.2
1.1
0.4
1.2
0.8
0.4
0.3
4.6
0.3
58

4.2
3.1
1.5
10.8
2.4
2.6
1.4
1.6
2.5
2.5
5.6
3.2
1.3
4.9
2.0
3.7
3.1
3.3
2.6
3.1
3.2
1.9
2.5
3.8
5.2
1.2
1.1
2.4
1.0
2.4
2.5
1.2
0.5
0.7
1.1
0.9
0.5
3.1
0.5

-0.9
-0.1
-0.9
-0.7
1.2
0.8
-0.7
0.2
-0.8
0.2
2.6
-0.2
-3.5
2.5
-0.1
-0.8
-0.4
0.7
0.1
0.6
1.4
-0.5
0.2
-0.7
1.2
-0.4
-0.6
-0.1
-0.6
-0.5
-0.7
0.1
0.1
-0.5
0.3
0.5
0.2
-1.5
0.2

Table 10. (Continued)
89
90
91
92
93
95
96
97
98
99
100
101
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
121
122
123
124
125
126
127
128
129
130
131
132

Streptomyces drozdowiczii
Streptomyces drozdowiczii
Streptomyces zaomceticus
Gordonia namibiensis
Rhodococcus opacus
Micrococcus yunnanensis
Streptomyces griseorubens
Streptomyces lividans
Nocardia caverna
Streptomyces violascens
Streptomyces drozdowiczii
Streptomyces griseus
Streptomyces coelicoflavus
Streptomyces malachitospinus
Streptomyces libani
Nocardia asteroides
Streptomyces spongiae
Streptomyces parvulus
Streptomyces olivoverticillatus
Streptomyces chartreusis
N/A
Streptomyces hawaiiensis
Streptomyces cinereospinus
Streptomyces intermedius
Streptomyces chartreusis
Streptomyces chartreusis
Streptomyces griseocarneus
Streptomyces cyanoalbus
Rhodococcus erythropolis
Streptomyces atratus
Streptomyces chartreusis
Streptomyces cinereorectus
Streptomyces diastatochromogenes
Streptomyces chartreusis
Streptomyces drozdowiczii
Streptomyces platensis
Rhodococcus opacus
Rhodococcus opacus
Streptomyces rishiriensis

12.6
5.3
18.1
16.7
5.5
15.5
7.6
8.7
0.7
2.4
1.8
1.1
1.6
1.7
1.7
1.2
1.6
1.1
1.5
1.4
0.9
0.9
1.1
3.6
3.2
1.2
0.1
0.5
2.7
2.3
0.9
1.0
0.8
4.0
2.3
0.8
1.0
5.7
0.6
59

11.1
9.4
11.1
14.6
4.0
10.4
11.2
6.3
0.6
1.8
1.0
1.3
0.7
1.6
1.8
1.2
0.8
1.9
1.1
2.1
0.8
0.6
1.5
3.5
1.4
1.6
0.1
0.3
4.3
1.6
0.9
1.5
1.2
2.4
1.3
0.9
3.8
5.6
0.9

-1.5
4.1
-7.0
-2.1
-1.5
-5.1
3.6
-2.4
-0.1
-0.6
-0.8
0.2
-0.9
-0.1
0.1
0.0
-0.8
0.8
-0.4
0.7
-0.1
-0.3
0.4
-0.1
-1.8
0.4
0.0
-0.2
1.6
-0.7
0.0
0.5
0.4
-1.6
-1.0
0.1
2.8
-0.1
0.3

Table 10. (Continued)
133
Streptomyces drozdowiczii
2.3
9.3
7.0
134
Rhodococcus opacus
4.2
5.1
0.9
135
Streptomyces angustmyceticus
1.1
0.8
-0.3
136
Streptomyces drozdowiczii
1.7
1.7
0.0
137
Streptomyces purpurescens
1.4
1.3
-0.1
138
Streptomyces exfoliatus
5.5
1.6
-3.9
139
Streptomyces septatus
1.3
19.9
18.6
140
Streptomyces rochei
1.1
1.1
0.0
141
Streptomyces angustmyceticus
0.9
0.8
-0.1
142
Streptomyces olivoverticillatus
1.5
1.3
-0.2
143
Streptomyces hirsutus
1.3
4.9
3.6
144
Streptomyces angustmyceticus
1.1
1.3
0.2
145
Streptomyces olivochromogenes
1.0
1.2
0.2
146
Agromyces lapidis
2.0
1.7
-0.3
147
Rhodococcus opacus
2.3
3.2
0.9
149
Arthrobacter kerguelensis
1.3
1.1
-0.2
150
Streptomyces exfoliatus
1.0
1.2
0.2
152
Streptomyces tendae
1.4
1.1
-0.3
153
Streptomyces lavendulae
2.2
1.7
-0.5
154
Mycobacterium parafortuitum
3.1
2.6
-0.5
155
Streptomyces malachitospinus
1.4
1.7
0.3
156
Streptomyces pactum
2.4
1.3
-1.1
157
Streptomyces olivaceus
2.2
1.1
-1.1
158
Streptomyces malachitospinus
2.7
1.3
-1.4
159
Streptomyces olivaceus
2.7
2.0
-0.7
160
Streptomyces praecox
1.8
0.5
-1.3
161
Streptomyces malachitospinus
0.7
0.7
0.0
162
Streptomyces griseoaurantiacus
0.2
0.5
0.3
163
Streptomyces griseoplanus
0.1
0.1
0.0
164
Streptomyces malachitospinus
0.4
1.0
0.6
165
Streptomyces malachitospinus
1.1
1.1
0.0
166
Streptomyces malachitospinus
0.1
0.6
0.5
713
Micrococcus sp.
1.0
1.1
0.1
* Listed are the strain numbers associated with each of the isolate identities along with the
crude extract mass yield from both modified and unmodified cultures as well as the comparison
between the two. Positive change indicates the modified culture’s crude extract possessed more
mass and negative change indicates the unmodified culture’s crude extract possessed more
mass.
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discovered from Actinobacteria confer some form of bioactivity against other bacteria, and the
antibiotic resistance seen in pathogenic bacteria is proving to be a worldwide issue. Therefore
we decided that in order to properly assess the presence of antibacterial bioactive secondary
metabolites, we needed to a panel of bacteria that could be used to do so. We wanted to ensure
if any bioactivity were identified, it was novel; therefore we utilized clinical isolates in the
screening process. The clinical isolates were comprised of the ESKAPE pathogens, which are
responsible for majority of hospital-acquired infections in the United States and well
characterized as possessing resistance to antibiotics (8). The 296 crude extracts, when solvated
in DMSO to a concentration of 5 mg mL-1, were screened for antimicrobial activity against all of
the ESKAPE pathogens using a MIC assay. A heat map was constructed to represent the
bioactivity of only the active extracts against the ESKAPE pathogens individually, the combined
activity for the Gram-positives, the combined activity for the Gram-negatives and collective
activity for all six (Figure 7). Of the 296 crude extracts, 78 (~26%) possessed bioactivity against
one or more of the ESKAPE pathogens (Appendix 2). The genera responsible for the activity
seen in these 78 crude extracts are Streptomyces, Nocardia, and Mycobacterium. As suggested
earlier, we looked at differences in crude extract mass of each of the Actinobacteria, which
provided little insight, but may have alluded to differences in gene regulation with a number of
the isolates. However, as we established bioactivity, we could further this insight and illustrate
actual biochemical differences between modified and unmodified isolates. As such, we looked
at changes in ESKAPE bioactivity between only the active extracts (Figure 8). Differences seen
between modified and unmodified isolate crude extract bioactivities occurred with almost every
sample. A few noteworthy crude extracts demonstrated higher levels of bioactivity against the
same pathogen when compared to their counterpart and a number showed bioactivity against
different pathogens compared to their counterpart. These differences indicate there are changes
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6 (Control)
6 (DNMTi)
8 (DNMTi)
15 (Control)
15 (DNMTi)
26 (DNMTi)
27 (DNMTi)
29 (Control)
30 (Control)
30 (DNMTi)
32 (Control)
32 (DNMTi)
34 (Control)
34 (DNMTi)
36 (DNMTi)
39 (Control)
40 (Control)
40 (DNMTi)
41 (Control)
42 (Control)
45 (Control)
45 (DNMTi)
46 (Control)
46 (DNMTi)
47 (Control)
47 (DNMTi)
48 (Control)
48 (DNMTi)
49 (Control)
51 (DNMTi)
54 (DNMTi)
56 (Control)
56 (DNMTi)
57 (Control)
58 (Control)
58 (DNMTi)
59 (Control)
59 (DNMTi)
61 (DNMTi)
68 (DNMTi)
69 (DNMTi)
70 (Control)
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74 (Control)
75 (Control)
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78 (Control)
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79 (Control)
81 (Control)
82 (Control)
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84 (Control)
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86 (Control)
87 (Control)
90 (Control)
99 (Control)
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104 (Control)
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109 (Control)
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110 (Control)
110 (DNMTi)
114 (Control)
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115 (Control)
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Figure 7. Heat Map of Crude Extract Bioactivity
All crude extracts were screened against the ESKAPE pathogens and the crude extracts with
any level of bioactivity were assembled in this heat map. Heat map demonstrates level of
activity to each of the individual ESKAPE pathogens, the Gram-positives, the Gram negatives,
followed by the compiled activity against all ESKAPE pathogens as a whole.
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Figure 8. Comparison of Activity Between Modified and Unmodified Crude Extracts
All crude extracts that possessed bioactivity were assembled and compared to their modified or
unmodified counterpart. Any portion of the bar graph that falls within the positive spectrum of
this graph indicates the unmodified crude extract possessed higher bioactivity than the modified.
Any portion of the bar graph that falls within the negative spectrum of this graph indicates the
modified crude extract possessed higher bioactivity than the unmodified
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being made to the regulation of these isolates, whether it is transcriptional, translational, or posttranslational, further characterization is required.

These efforts to disrupt gene regulation via inhibition of DNA methylation have resulted in
numerous changes thus far. We have observed differences in crude extract mass as well as
changes in bioactivity against the ESKAPE pathogens, however in order to bottleneck the
number of isolates we are working with, we needed to identify an approach to do so. We
needed to establish a minimum scaled score to ensure the crude extracts we were excavating
would provide adequate bioactivity upon purification. Therefore we determined any crude
extract possessing a combined scaled score of >= 8 would be a priority for purification and
characterization, while the remainder were archived. Of the 78 bioactive crude extracts, 17
(~22%) possessed a combined scaled score >= 8 (Figure 9). The genera responsible for these
higher scaled scores belonged to Streptomyces and Nocardia, 15 of which were crude extracts
from Streptomyces (Figure 10). These 17 offered a location with which to begin scaling up
growth of our collection for higher yields of crude extract in order to further purify and
characterize each of the extracts.

From the initial ranking data, we decided to move forward with sample 6 (Streptomyces
violarus) as this crude extract possessed a vibrant ruby color and diffusible pigments can be an
indicator of bioactive secondary metabolites (134). Aside from the coloration of the crude
extract, sample 6 control was able to effectively inhibit A. baumannii at 50 µg/mL and S. aureus
at 4 µg/mL and sample 6 DNMTi effectively inhibited E. faecium at 50 µg/mL and S. aureus at
10 µg/mL. Therefore we scaled up production and grew sample six in the presence and
absence of 1 µM 5-azacytidine in two liter Erlenmeyer flasks containing 1000 mL of SCA broth.
These flasks were kept at 28 °C in a shaking incubator under constant agitation for 28 days.
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Figure 9. Crude Extracts with High Levels of Bioactivity
Crude extracts were organized based upon level of bioactivity in order to determine a prioritized
system for future characterization.
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Figure 10. Overall Analysis of Crude Extract Bioactivity.
Total crude extracts used against the ESKAPE pathogens was 296, of which 78 possessed any level of bioactivity. Bioactive genera
included Streptomyces, Mycobacterium and Nocardia. Only 17 of these 78 possessed high levels of bioactivity, which included
species of the genera Streptomyces and Nocardia

Total=296

218

Bioactive
Inactive

61

Accept
Reject

The initial elements to analyze were to determine if there were a correlation between the crude
extract mass and bioactivities of the small scale and large scale. The difference in volume of
media was almost a 30-fold increase, while the fold change in crude mass extracted for the
unchallenged and challenged were 32-fold and 42-fold, respectively (Figure 11A). The
bioactivities of both of the large-scale crude extracts were almost 2-fold, with regards to S.
aureus bioactivity, of the small-scale (Figure 11B). E. faecium bioactivity remained the same
between small-scale and large-scale when challenged with 5-azacytidine, but bioactivity seen
with A. baumannii in the unmodified small-scale crude extract was now replaced with bioactivity
against E. faecium in the unmodified large-scale crude extract. We weren’t as concerned with
the level of activity as both the modified and unmodified demonstrated the same trend with the
primary difference being a 2-fold increase in bioactivity. Therefore we proceeded to purification
of the crude extract.

Initial High Performance Liquid Chromatography Coupled with Bioassay Guided
Fractionation
High performance (pressure) liquid chromatography is a very beneficial form of column
chromatography used by a number of fields for the purpose of separating complex mixtures.
The system involves pumping your mixture through a column (stationary phase) in a solvent
(mobile phase), mixture of solvents, or solvent-solvent gradient. The chromatogram displays the
retention times of the separated compounds. Each of the compounds within the mixture
interacts with the column and solvents differently; this interplay is what causes separation.
There are numerous detectors used with HPLC analysis, however we focused on ultraviolet
(UV) and electronic light scattering (ELS) detectors. We used two semi-preparatory silica
columns in tandem as our stationary phase. Our mobile phase used 100% hexanes for 5
minutes, followed by a 35 minute gradient from 0-100% EtOAc, after which 15 minutes of 100%
67
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Sample

Small-Scale
(milligrams)

Large-Scale
(milligrams)

Fold change
(Media)
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Figure 11. Small-Scale and Large-Scale Variations
Large-scale unmodified and modified crude extract masses were 32 and 42 fold higher than
small-scale masses, respectively (A). Large-scale unmodified and modified crude extract level
of bioactivity against the ESKAPE pathogens were both ~2-fold higher than small-scale
bioactivity (B).
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Figure 12. HPLC Outline and Chromatograms
Workflow and results of each of the HPLC purifications for sample 6 modified and unmodified crude extracts. Workflow and resultant
fractions of sample 6 unmodified crude extract (A); HPLC chromatogram for sample 6 unmodified crude extract, resulted in 10
fractions as well as baseline collections (B); Workflow and resultant fractions of sample 6 modified crude extract (C); HPLC
chromatogram for sample 6 modified crude extract, resulted in 9 fractions as well as baseline collections (D).

C

A

B

EtOAc, and concluded with 15 minutes of 1:1 EtOAc:IPA. This method yielded 10 fractions for
the modified crude extract and 11 fractions for the unmodified crude extract (Figure 12A-D).
After separating the two crude extracts into 21 separate fractions, we needed to determine
which portion possessed the bioactivity seen in previous bioassays. The screen was performed
against all of the ESKAPE pathogens in the same fashion as above and resulted with bioactivity
in two fractions from sample 6 control, F and baseline (Figure 13). Bioactivity was only
observed against S. aureus and was significantly reduced from bioactivity seen in prior
screenings, and the bioactivity that was originally observed against E. faecium was lost
completely. After performing bioassay with all of the fractions, we only possessed ~2.0 mg of
the bioactive fraction J, which we attempted to purify further with reverse phase HPLC, however
the mass acquired simply was not enough for further purification.

We learned a few important key factors with regard to our initial HPLC purification screening,
one of which was that we required much more crude extract mass in order to obtain higher
masses of purified fractions. Another important lesson learned was that a method needed to be
optimized for purification of the crude extract, as there were a number of issues with regards to
mobile phase optimization, stationary phase optimization and collecting of the fractions.
High Performance Liquid Chromatography Coupled with Bioassay Guided Fractionation
With initial large-scale purification we learned a number of valuable lessons, which we intended
to improve upon with further attempts at HPLC purification. Our first amendment involved
drastically increasing the crude extract mass, whereby we grew two liters of culture every 28
days, and three liters on the final 28 days, to a total of 13 liters for extraction. Each two-liter
interval was considered the same and crude extracts were combined, as such we concluded
with six individual crude extracts (Table 11). Our second amendment involved an extra
purification step for each of the samples in an attempt to ensure uniform solubility for our

70

25

Ef

Sa

Kp

Ab

Pa

Ec

Scaled Score

20
15
10
5

T
o n i)
tr
(C ol
)
o
C ntr
(C ol
)
o
D ntr
(C ol
)
o
E ntr
(C o l
)
o
F ntr
( C ol
)
o
G ntr
(C ol
)
o
H ntr
(C ol
on )
I ( tro
C
on l)
B
J
tr
as
el ( C o o l )
in
e ntr
(C o l
on )
tr
ol
)
B

(C

N

A

(D

M
N
D

e

in
el
as
B

M

)

)

Ti

)

Ti
M
I(

(D

N

Ti
M
H

N
(D

G

(D

N

M

Ti

)

)
Ti

)
M

F

(D

N

Ti

)

E

D

(D

N

M

Ti

)
M

Ti
C

(D

N

M
N

(D
B

A

(D

N

M

Ti

)

0

Fraction

Figure 13. Bioactivity of HPLC Fractions
All fractions from HPLC purification of modified and unmodified sample 6 were screened against
the ESKAPE pathogens to determine which of these possessed bioactivity. None of the
fractions except for fraction J and the baseline fraction from unmodified sample 6 possessed
bioactivity and only against S. aureus.
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Table 11. Two-Liter Fermentation cycles and Partitioned Masses
Partition
Crude
EtOAc
Insoluble

First (mg)
212.0
65.2
25.6

Second (mg)
180.2
111.6
9.6

Third (mg)
135.6
56
7.8

Fourth (mg)
240.3
151.6
20.6

Fifth (mg)
210.6
110.3
12.3

Sixth (mg)
330.7
160
75.6

H 2O
100.5
40.9
58.1
55.6
66.9
59.6
* Listed above are the mass yields for each of the two-liter fermentation cycles including crude
mass as well as the mass for each of the partitions. Slight overall losses can be attributed to
residual crude extract within the original collection vials.
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complex mixture of compounds. This involved re-suspending each of our crude extracts in
EtOAc followed by partitioning with an equal volume of double distilled H2O in a separatory
funnel, and collecting each of the layers (EtOAc soluble, insoluble, and H2O soluble) into
separate pre-weighed 20 mL scintillation vials, this was repeated three times to ensure
complete separation. The collections were dried under constant flow of air and weighed. After
an initial weigh in, a small mass of each partition was collected for bioassay (Table 12). Each of
the partitions were screened against the ESKAPE pathogens to ensure bioactivity towards E.
faecium and S. aureus were still present amongst each extraction as well as to identify which
partition possessed bioactivity. For the purpose of identifying whether or not activity was
present, MICs were not performed; instead all partitions were screened at a test concentration
of 25 µg mL-1. At this concentration, all of the crude extracts, as well as the EtOAc and insoluble
partitions possessed bioactivity towards the two pathogens, while the H2O layer only possessed
activity in a few of the extractions. This circumstantial activity alluded to a number of
possibilities, the first being we were unable to completely remove all bioactive compounds from
the H2O partition in all of the extractions, a second being multiple compounds possessing
bioactivity and varying polarities are present in our complex mixture and therefore our partitions.
Our most likely scenario is the former, as a result of bioactivity being seen in only a few of the
H2O partitions and not all.

The increased number of fermentations alongside partitioning provided ~650 mg of the EtOAc
partitioned crude extract to be purified via HPLC. This mass was suspended in 4:6 hexanes:
EtOAc to a final concentration of 75 mg mL-1 for normal-phase HPLC using one semipreparatory silica column as the stationary phase. Our mobile phase used 100% hexanes for 5
minutes, followed by a 35 minute gradient from 0-100% 1:1 EtOAc:IPA, and concluded with 15
minutes of 100% 1:1 EtOAc:IPA. This method is slightly modified from our former method, which
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Table 12. Total Mass for Each Two-Liter Fermentation Cycle

Partition

First
Extraction
(mg)

Second
Extraction
(mg)

Third
Extraction
(mg)

Fourth
Extraction
(mg)

Fifth
Extraction
(mg)

Sixth
Extraction
(mg)

Crude mass
removed for
bioassay

5.0

5.0

3.3

7.8

4.9

6.0

Crude mass
remaining

8.7

5.2

7.1

2.3

12.7

5.2

EtOAc mass
removed for
bioassay

5.0

4.3

5.0

6.6

7.4

5.0

EtOAc mass
remaining

60.2

107.3

51.0

145.0

102.9

155.0

Insoluble mass
removed for
bioassay

5.0

2.7

1.3

4.5

5.0

6.9

Insoluble mass
remaining

20.6

6.9

5.5

16.1

7.3

68.7

H2O mass
removed for
bioassay

2.5

4.3

5.3

7.8

8.3

8.1

H2O mass
remaining

98.0

36.6

52.8

47.8

58.6

51.1

Sum

205.0

172.3

131.3

237.9

207.1

306.4

Overall
Percent lost

3.3%

4.4%

2.4%

1.0%

1.7%

7.3%

* Listed above are the total masses from the partitions from each of the two-liter fermentation
cycles. This includes all of the masses removed for bioassay as well as the remaining mass and
finally the total mass to determine the amount lost from each partition.
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used a mobile phase of EtOAc followed by a 1:1 EtOAc:IPA wash and a single silica column as
opposed to two in tandem for our stationary phase. These minor modifications provided
significantly better separation of the compounds present in the mixture and yielded 18 fractions
(Figure 14A-B, B not present yet). In order to determine which of these fractions possessed
the bioactivity seen in previous screenings, they were challenged against the ESKAPE
pathogens. Fractions N and O retained activity against both E. faecium and S. aureus, which
therefore required even further HPLC purification. We were unconcerned with the MIC of these
fractions due to the limited masses we acquired, and therefore only analyzed each of the
fractions as bioactive or inactive. The retention times for both fractions N and O indicated that
the compounds present were more polar as they did not elute until majority of the mobile phase
was 1:1 EtOAc:IPA. Further purification via HPLC utilized the system in reverse phase, which
involves a hydrophobic stationary phase.

We began by suspending fractions N and O in a 20% solution of tetrahydrofuran (THF) in
acetonitrile (ACN) and used an analytical C8 column as our stationary phase. Our mobile phase
used 9:1 H2O:20%THF:ACN for five minutes, followed by a 35 minute gradient from 10-99% of
20%THF:ACN, and concluded with 15 minutes of 99% of 20%THF:ACN. This method was used
for both fractions for purification and yielded seven sub-fractions each (Figure 14C,
Chromatogram needs to be obtained). Once again we needed to determine which of these
sub-fractions possessed the bioactivity seen in previous screenings, as such, they were all
challenged against the ESKAPE pathogens. Fractions 2ND and 2OD retained bioactivity against
both E. faecium and S. aureus, while fraction 2OC displayed a hint of bioactivity as there was a
severe growth defect with both E. faecium and S. aureus. As we now had even more limited
masses than prior ESKAPE screenings, we once again limited our analysis to determine if the
fractions were bioactive or inactive. This clear indication of which fractions possess bioactivity
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has allowed for further characterization of our compound using mass spectrometry, H1 NMR and
C13 NMR.
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Figure 14. Modified HPLC Workflow and Chromatograms
Workflow and resultant fractions from EtOAc partition of sample six 13-L scale-up fermentations for normal phase as well as reverse
phase HPLC purification (A); HPLC chromatogram for sample 6 unmodified EtOAc partition (B); HPLC chromatogram for sample 6
unmodified fraction N (C); HPLC chromatogram for sample 6 unmodified fraction O (D).

B

A

Discussion

It has long been known that Actinobacteria in the soil can provide a plethora of bioactive
secondary metabolites, but have we just scratched the surface? We know that many species
within the phylum Actinobacteria possess very diverse secondary metabolism, which can aid in
their survival (77). Although some of the best described and most helpful for humanity have
been antibiotics, which inhibit enzymes and cellular processes, Actinobacteria can also
manufacture siderophores, for iron acquisition (135), spore pigments, which have been shown
to provide some level of UV protection (136), as well as enzymes specialized for degradation,
such as chitin binding proteins, which can aid in chitin degradation as a carbon and nitrogen
source (137). The multitude of secondary metabolic potentials arise when Actinobacteria are
stressed in the form of threats by other micro- or macroorganisms, nutrient depletion, and
environmental stressors such as temperature and pH. These secondary metabolite products
provide the structures and scaffolds we need to identify novel therapeutics and encouraging
these organisms to produce them is only the first step.

Actinobacteria Diversity
Actinobacteria as a phylum have undergone numerous taxonomical classification events, only to
be adjusted as technology advances. Originally classified as thread bacteria that closely
resemble filamentous fungi, their organization has been adapted to include cell wall
composition, morphological features, biochemical analysis, 16S rRNA gene sequencing, and
nowadays we fall to whole genome sequencing (65, 138, 139). The constant evolution of
Actinobacteria taxonomy is a result due to the remarkable diversity within this phylum. As each
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new method of classification arises, we find outliers that do not match the necessary
descriptions that fall within certain classes, genera, or species. An issue seen with cell wall
composition as a mode of classification is that bacteria are typically classified as Gram-positive
or –negative. This is based upon a Gram’s stain, which will either indicate a thick peptidoglycan
layer and single membrane (Gram-positive) or a thin peptidoglycan layer and two membranes
(Gram-negative) (140). However the issue that arises is when bacteria don’t match either of
these descriptions and are considered Gram-variable, this can include Actinobacteria such as
Actinomyces, Corynebacterium, and Arthrobacter (141). Biochemical analysis for classification
saw similar issues as seen with cell wall composition taxonomy. Between the species there
were a number of isolates that demonstrated similar cell-wall characteristics, and while the
biochemical analyses could differentiate between a few, overlap was still observed, as seen with
Mycobacterium spp. (142). Along with the advent of gene sequencing, the 16S rRNA gene
became the method by which prokaryotes would be organized (143). As there are conserved
regions of the 16S rRNA gene within a genus, there are also regions of variability that can be
species specific, which is what gives this technique such remarkable cataloguing potential. As
with all methods thus far, problems have arisen and while it is well known that bacteria possess
16S rRNA genes in numerous locations scattered throughout their chromosome, it was found
that bacteria can also possess 16S rRNA genes that vary from one another as seen in
Thermomonospora chromogena, which also happens to be a member of Actinobacteria (144).
With whole genome sequencing becoming increasingly affordable, 16S rRNA gene
classification may eventually lose its place, however it can still organize prokaryotes based upon
their phylum, class, order, family and in a majority of instances, genus (66).

Within our unique collection of Actinobacteria we utilized 16S rRNA gene sequencing in order to
identify the strains. With the objective of identifying a high throughput technique for isolating
Actinobacteria we began by using 16S rRNA gene sequencing as an initial method for
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identifying the bacteria we were working with. Using this technique, we were able to become
familiar with Actinobacteria characteristics, which aided in rapid detection thereby eliminating
the need for 16s rRNA gene sequencing. As we were isolating these bacteria with the intention
of modifying already characterized isolates to unlock dormant or overlooked metabolism, we
only resorted to 16S rRNA gene sequencing only when isolates possessed characteristics
unlike those of Actinobacteria. In such cases we first ensured they were Gram-positives or
repeatedly demonstrated a Gram-variable phenotype. Concurrent with literature, we have found
that majority of our isolates for which we have identified belong to the genus Streptomyces. The
majority of the isolates within the strain collection possess some level of semblance to the
identified Streptomycetes therefore these bacteria which share a likeness were added to the
collection (68). Regardless of the dominance of Streptomycetes in our environmental samples,
we have still managed to isolate and identify a variety Actinobacteria, which provides alternative
secondary metabolite potential in our search. We believe the diversity in our Actinobacteria
collection is due to the variety of locations our environmental samples were obtained. Thus far
we have primarily focused on terrestrial samples, however we have scavenged a few
Actinobacteria in our collection from other areas including aquatic and arid environments. As we
continue to isolate and identify Actinobacteria, we anticipate that the diversity will continue and
grow as we move to more unique environments such as deep-sea sediments, sponges, and
high-altitude soils.

Many researchers in the Actinobacteria world focus their efforts on locating novel genera and
species from exotic locations in an effort to discover new chemistry that allows the bacteria to
survive in these unique environments. We however are combining this common approach while
simultaneously focusing on cultivation of as many isolates as possible from environmental
samples. We have looked at a variety of locations for Actinobacteria including in our back yard
or a farm, which has the potential to provide immense diversity. For numerous soils it is
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estimated that the population density is ~ 1 billion bacteria per gram, while the variety of species
can be between 4,000 and 50,000 (145, 146). Actinobacteria are only thought to account for
between 2 – 9% of the overall population, this would suggest a large range of potential
actinobacterial isolates (80-4,500 Actinobacteria g-1) (145). Most of our samples yielded a
number of isolates that falls within this range perfectly, as shown with our Soil 1 environmental
sample from a Ft. Meyers farm. Soil 1 was able to provide 32 Actinobacteria that we were able
to identify into our strain collection. Taking into consideration the dilution series undergone and
volume plated, we see that the estimated number present in the original sample was ~1,600
Actinobacteria g-1. This number only represents the Actinobacteria we were able to culture
within the laboratory, which suggests we may be missing potential additions to our collection.
One study proposed that the use of many different media types would increase the chance of
identifying novel members of the phylum, their results suggest that the number of isolates
acquired was higher when more media types were used (147). We attempted to use a greater
variety of media and methods initially, however it did not seem a feasible option with the number
of environmental samples we possess. Although the exact media composition for optimal
growth of Actinobacteria is unknown, our two low-nutrient media provide an excellent basis for
high throughput isolation.

Drug Discovery
With the introduction of penicillin by Alexander Fleming in 1928 and its subsequent release to
the public in the 1940s, so began the era of natural products drug discovery (86). The field
delved further with the introduction of actinomycin and streptomycin by Selman Waksman
shortly after (87, 88). Antimicrobial resistance spurred drug discovery into a never-ending
endeavor to prevent infection and soon it seemed all pharmaceutical companies and drug
discovery researchers were growing microorganisms in the search for antibiotics. This search
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for anti-infective agents did not come without a price tag or regulations, which were becoming
more and more stringent. In the 1970s, many pharmaceutical companies were realizing that
natural product drug discovery branches were becoming a financial burden as the proverbial
“low hanging fruit” was now out of reach (148). As the 1990s came about, we were looking at a
revolution within the drug discovery world and that was combinatorial chemistry, a method by
which tens of thousands of chemical structures can be tested at once as potential therapeutics
(90). One of the issues with combinatorial chemistry is that the synthetic capabilities of chemists
cannot compete with that of nature, and therefore natural products chemistry has produced
scaffolds and compounds that cannot be mimicked in the laboratory. As seen with
Actinobacteria classification, new technologies provided alternative approaches to searching for
novel bioactive compounds. Technological advancements have led to resurgence in natural
product drug discovery. Liquid chromatography advancements now allow for accurate and
replicative separating of soluble compounds and mass spectrometry has provided analysis of
crude extracts, which can detect trace amounts of individual compounds. Novel cultivation
techniques cater the isolation of previously unattainable microbes to be grown in lab conditions
and whole genome sequencing has allowed for genome mining in the search for genes
homologous to those found in known biosynthetic pathways. All of these coupled to one another
have thrust natural product drug discovery in new directions previously unexplored.

Today, drug discovery looks very different than before as novel techniques are used in
numerous applications. Bioactive secondary metabolites have been found in unorthodox
locations such as a Colorado iron-rich freshwater spring by a group from Oklahoma (149). Six
new compounds were identified from fungi found within a microbial mat and the group was able
to characterize clearanols A-E and disulochrin (149). Of these six natural products disulochrin
demonstrated bioactivity against methicillin-resistant Staphylococcus aureus and clearanol C
showed weak bioactivity against Candida albicans biofilm formation (149). Identifying microbes
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from unique locations can lead to remarkable chemistry as these organisms have developed
methods for thriving in such environments. An alternative habitat that has been explored to yield
new secondary metabolites is sea life. Former explorations of marine life such as tunicates
suggested that compounds found within were synthesized by the Ascidians (150). While they
are a prolific source of natural products, it was later found that these compounds were actually
produced by the endophytic bacteria. This was elucidated using genome sequencing where it
was found that the Prochloron didemni did not possess the necessary genes for synthesis of the
antitumor polyketides known as patellazoles (151). The combination of new habitats and whole
genome sequencing allowed natural products to identify the specific producer of the
compounds.

In the constant struggle of imitating the natural environment within the lab there have been
numerous attempts at replicating such conditions. In order to mirror nutrient fluctuations seen in
the environment, groups in Germany have devised a clever way including continuous culture of
Aspergillus nidulans, one of the model organisms used to study fungal genetics. This
continuous culture could be modified to mimic nitrogen, phosphorous and carbon limiting
conditions that could occur in the environment (152). Under nitrogen and phosphorous
limitations silent polyketide synthase genes were differentially expressed when compared to
standard growth conditions (152). A search that yielded novel secondary metabolites utilized a
novel growth technique that allowed bacteria to grow in their natural environment. Using a multichannel device known as an isolation chip or iChip, the group was able to isolate previously
unculturable microbes (153). This iChip consists of hundreds of diffusion chambers made up of
through holes with semi-permeable membranes on either side (153). The process involves
loading each of the wells with a sample of soil that has been diluted to roughly one cell per 20
microliters of molten agar, assembling the remainder of the iChip, and then burying it where the
original soil sample was obtained (153). This method was used by Ling et al. to isolate and
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identify the novel cell wall inhibitor, teixobactin from the new species Eleftheria terrae (154).
Prior to identification of this compound, this group of Gram-negatives were not known to
produce any antibiotics, which exposes how little is known about bacteria in their natural
environment (154).

Although bacteria possess seemingly limitless diversity when it comes to secondary
metabolites, a struggle commonly seen is the abundance with which they are synthesized.
Advancements in instrumentation used for detection and analysis of metabolite production has
given rise to the term “metabolome.” The metabolome is in reference to the overall metabolite
production by an organism, much the same, as the genome and the associated genes or the
proteome and proteins produced. Improvements to mass spectrometry have allowed for
detection of trace loads of a compound in a mixture. Using HPLC and mass spectrometry in
tandem grants separation as well as mass detection of crude mixtures resulting in a metabolic
profile. After further purification, even the insignificant portions of the amalgam of compounds
could be identified. Many metabalomic profiles exist from bacteria today; they can be used to
determine effect of nutrient starvation, mutation, temperature or pH stressors on metabolite
production. A group at the University of Wisconsin – Madison were able to discover analogs of a
known compound using liquid chromatography coupled mass spectrometry (LCMS) (155). This
analog, bottromycin D possessed slightly lower levels of bioactivity than the original bottromycin
A2, however identifying the compound cements LCMS as a promising technique for future
analysis of metabolites (155).

Our research has utilized a number of these methods listed above, which could be what drives
the immense diversity of our collection. We have not only obtained samples from diverse
locations, but we also are using HPLC coupled with mass spectrometry as well as NMR
techniques to elucidate the structure of a compound. Our environmental samples include soil
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from numerous locations including farms (higher nitrogen levels), high altitudes (lower oxygen
levels) and forests (higher organic content). Not only does our environmental sample collection
have a variety of soils, but we also possess numerous sponges, sand from arid and high
temperature regions, as well as shallow and deep-sea sediments. This variety of conditions can
play a significant role in the behavior and lifestyle of the native microbes and by using such a
wide variety environmental samples we have been able to demonstrate similarities to literature
in acquiring a diverse collection of Actinobacteria. Interestingly, some of our environmental
samples that have provide the most numerous isolates of Actinobacteria have been locations
that have had ample traffic by grazing animals. Our biggest contributor with regards to the
Actinobacteria collection was from a soil sample procured from horse stables, however this has
been only an observation thus far. A hypothesis that could provide insight to this observation is
that grazing animals leave in their wake a myriad of particulate organic matter, which is readily
colonized by Actinobacteria, as they possess the necessary metabolism to decompose such
substances. Of the 13 different Actinobacteria that possessed high levels of bioactivity against
the ESKAPE pathogens, all were from soil samples that had interaction with grazing animals.
This suggests the bacteria within the soil samples may have had interactions with mammalian
associated bacteria, therefore requiring them to mount defensive strategies that persisted
throughout lab cultivation. An alternative theory suggests the soil may have been supplemented
with lime, which is commonly used as a remedy for low soil pH and help plants and fields
flourish, and has also been shown to enhanced presence of Streptomycetes (156, 157).
Furthermore majority of the crude extracts that possessed high levels of bioactivity were from
the genus Streptomyces, which has historically been a primary source of antibiotics. Majority of
our bioactivity is towards our Gram-positive organisms E. faecium and S. aureus, which seems
fairly common with drug discovery campaigns. Within the literature it seems that bioactive
compounds trend towards the Gram-positives for a number of reasons including two attributes
of the Gram-negatives, an outer cell membrane and efflux pumps (158). It has been
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demonstrated that antibiotics with intracellular targets possessed by both Gram-positives and
negatives can affect only the Gram-positives and efflux deficient Gram-negatives (117).

Although we have successfully extracted bioactive secondary metabolites from our cultured
Actinobacteria, there are numerous improvements that could provide better yields. One such
improvement could be to increase aeration within our flasks. It is suggested that for cultivation of
Streptomycetes, there should be 4-10 fold volumes of air compared to that of the liquid medium.
Currently in our methods we are using a 1:1 ratio of liquid media to air, which may not be
enough for the bacteria to properly thrive. We have also noticed significant clumping of our
bacteria in liquid cultures, primarily the Streptomycetes. This is a common issue that can be
dealt with in numerous ways including addition of sucrose, polyethylene glycol, or using baffled
flasks (159). As such we will be optimizing a method to prevent clumping and perhaps
optimizing even further the necessary volumes for increased production of bioactive secondary
metabolites. Additional to our potentially sub-optimal aeration, our extraction methodology
focuses solely on secondary metabolites, which are soluble in EtOAc. This could be rectified
with modifications to procedure that involve drying the entire growth culture prior to extraction.

Epigenetics
Many efforts have been devoted to discovering new methods of unlocking silent metabolic
pathways in Actinobacteria and other natural product-producing organisms. Of these methods
there have been attempts of small molecule or chemical, co-cultivation, or genome mining
elicitation of these cryptic genes. Much of the literature regarding co-cultivation suggests that
quorum sensing molecules or presence of a nutrient competitor elicits the production of
secondary metabolites (160). Genome mining has also proved a potential for novel metabolites,
as shown with S. coelicolor, which displayed over 20 theorized secondary metabolite
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biosynthetic pathways (78). However, our search for silent metabolic pathways involves
epigenetic modification of Actinobacteria using small molecules. This has only been performed
a handful of times, however for fungal elicitation it has been very successful with identification of
novel metabolites. A study performed in 1995 by Fernandez et al. and Novella and Sanchez
discussed the differences in production of rhodomycin from S. antibioticus (161, 162). It was
noticed that the cultures with 5-azacytidine began producing the anthracycline after only six
hours of growth, while the control didn’t display any signs of production even after four days of
growth (161). The study by Fernandez et al. attributed the changes in anthracycline production
to low levels of methyltransferase in the 5-azacytidine challenged culture stating that
methyltransferase activity was as low as 50% of that seen in the control (161). Fernandez et al.
were looking for effects of DNA methyltransferase inhibitors on the overall growth and
development of Streptomyces, which was not limited to secondary metabolite production, but
other characteristics as well. In the subsequent study by Novella and Sanchez, it was
demonstrated that neither DNA, RNA or protein synthesis in S. antibioticus were inhibited by 5azacytidine, yet this study confirmed the low level of activity from methyltransferases (162).
Another study that used 5-azacytidine as a small molecule elicitor of secondary metabolite
biosynthesis was performed at Banaras Hindu University in Varanasi, India. This study by
Kumar et al. involved exposing S. coelicolor to varying concentrations of 5-azacytidine to
compare crude extracts bioactivity to untreated cultures. Kumar et al. tested crude extracts from
each of the S. coelicolor cultures at the varying concentrations against five human pathogenic
bacteria (108). Using a combination of Kirby-Bauer disk diffusion and MTT assays, they
determined that a concentration of 25 µM was sufficient to induce antibacterial activity (108).
The group continued to HPLC and MALDI-TOF/mass spectrometry analysis of the crude
extracts to derive differences between the 25 µM and untreated growth cultures. Their
conclusion alludes to antibacterial activation after epigenetic modification as their control culture
produced only five compounds, while their modified produced 12 (108). Although the study
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provided compelling evidence to suggest epigenetically modifying S. coelicolor induced
inhibitory agents after a threshold concentration was achieved, there was no mention of the
inhibitory action of 5-azacytidine against the human pathogens at the concentrations mentioned.
In our study we overcame this obstacle by ensuring 5-azacytidine concentrations used would
not affect growth of our pathogens. We also ensured the concentration of 5-azacytidine would
not inhibit growth of our Actinobacteria as we optimized the concentration used rigorously. In
our studies of epigenetic modification of Actinobacteria we have attempted to ensure each of
our processes are optimal for a high throughput screening campaign. By identifying optimal the
optimal cultivation period, media, concentration of epigenetic modifier, and catering to multiple
growth types present in Actinobacteria, we believe this high throughput endeavor will
successfully unlock cryptic metabolic pathways.

As a result of our rigor, we have successfully observed differences in production and
antibacterial activity of our crude extracts from modified and unmodified Actinobacteria. As
mentioned previously, the masses associated with our crude extracts vary greatly, however the
differences in mass between modified and unmodified cultures demonstrates the level of
change each of the Actinobacteria are undergoing. These changes in mass primarily indicate
that the proportions of product are different, which we believe is a direct effect of our epigenetic
modifier. We have also established diversity in the level of antibacterial bioactivity between
modified and unmodified cultures indicating different compound production between the two. It
has been demonstrated that mutations in gene promoters and changes in methylation patterns
can alter expression of the subsequent genes (45, 46, 95). Therefore we hypothesize that the
variations in crude extract mass and bioactivity against the ESKAPE pathogens could be a
result of augmented regulation due to gene promoter de-methylation. This of course suggests
three outcomes for secondary metabolite biosynthesis gene promoters; they can be expressed
more frequently, less frequently, or can be unaffected. This interpretation would provide
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adequate rationale for our modified crude extracts yielding higher, lower or equal mass and
bioactivity compared to the unmodified crude extracts.

As we near the potential of a post-antibiotic era, we require new therapeutics that can combat
the rise of resistance. Actinobacteria have historically contributed to majority of the antibiotics
we possess today, and continue to provide natural products and natural product derivatives. Our
results demonstrate the abundance of compounds yet to be identified in both new organisms as
well as the well established. The identification of our lead compound has and will remain our top
priority as it has demonstrated such inhibitory potential of S. aureus and E. faecium. Thus far we
have successfully purified our crude extract from the large-scale fermentation of S. violarus via
HPLC and have moved to structure elucidation. The structure of our compound thus far, when
comparing the NMR and mass spectrometry data, seems to possess characteristics often
associated with anthracyclines. The phenotype of our compound also suggests anthracycline as
it retains the same ruby pigmentation often associated with this class of drug. Anthracyclines
are characterized as possessing anti-tumor capabilities as well as have been observed to inhibit
Gram-positives, although we have not yet performed cytotoxic screening of our compound, we
have noticed inhibition of only Gram-positives thus far. Although the exact mechanism of action
of anthracyclines is perpetually debated, it has been shown resistance in Gram-negatives may
be due to efflux pumps (117).
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Future Directions

Preliminary results suggest the bioactivity of our extract is due to an anthracycline compound
based upon the ruby pigment, the Gram-positive specific bioactivity, and initial NMR data. In
order to properly elucidate the structure of our lead compound, it would be beneficial to obtain
significantly more crude extract for purification. We have performed numerous purifications via
HPLC in order to obtain as much pure compound as possible, yet we seem to be left with
minuscule amounts. Regrettably the long cultivation period and low extraction yield results in
providing only preliminary data that suggests subtle hints of the structure of our lead compound.
Therefore significantly more crude extract is needed in order to purify higher more. Alternatively,
we could also optimize our growth period and determine at what point S. violarus is producing
the highest yield of our bioactive compound. This can be done in a few ways including a
bioactivity based approach or a mass spectrometry approach, either would provide insight into
the abundance at different growth stages. Alternatively, it would also be worthwhile performing
whole genome sequencing on the isolate to determine the gene clusters responsible for our
compound. This information would potentially allow us to identify biosynthesis and regulatory
pathways, which would allow for optimized growth and production. Genome mining could also
help identify otherwise unknown alternative secondary metabolite biosynthesis pathways, which
could harbor previously unseen chemistry. After establishing the structure of our lead compound
we will focus on further characterizing the bioactivity seen including whether the compound is
bacteriostatic or bactericidal in nature, cytotoxicity of the compound and whether this compound
has the ability to affect bacteria within a biofilm.
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We also plan to continue growing and modifying the Actinobacteria strain collection followed by
determining antibacterial activity against the ESKAPE pathogens. Thus far we have successfully
grown and extracted a large number of isolates, however, as the collection continues to grow,
so must the extractions. We possess a number of environmental samples we have been unable
to cultivate organisms from, however, this requires further optimization that we will achieve. We
have identified a number of high activity crude extracts, which have provided a number of
avenues with which to pursue in further large-scale culturing followed by purification and
characterization. In an attempt to further identify the impact of our DNMTi, we would also like to
establish a metabolome profile for our unmodified and modified organisms. This of course could
not be performed on all organisms we cultivate; however it would be interesting to analyze our
crude extracts that possess high levels of bioactivity against the ESKAPE pathogens and
demonstrate differences between the modified and unmodified samples.
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Strain Collection ID
1
5
6
8
10
11
12
13
14
15
16
17
18
19
20
21
22
25
26
27
29
30

Genus
Rhodococcus
Rhodococcus
Streptomyces
Streptomyces
Streptomyces
Gordonia
Rhodococcus
Nocardia
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Arthrobacter
Gordonia
Aeromicrobium
Rhodococcus
Gordonia
Rhodococcus
Streptomyces
Streptomyces
Mycobacterium
Streptomyces
109

Species
Rhodochrous
Rhodochrous
Violarus
Beijiangensis
Coelicoflavus
Namibiensis
Rhodochrous
Vermiculata
Platensis
Violarus
Albiflavescens
Corchorusii
Protophormiae
Namibiensis
Tamlense
Phenolicus
Terrae
Rhodochrous
Chromofuscus
Acrimycini
Parafortuitum
Macrosporeus

Table A - 1. Identified Isolates in Actinobacteria Strain Collection

Appendix

Media
SCA
SCA
SCA
AGS
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA

Method
Method 3
Method 1
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 2
Method 2
Method 3
Method 2
Method 1
Method 1
Method 3
Method 3

Sample
Soil 2
Soil 2
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 1
Soil 1
Soil 2
Soil 2
Soil 2
Soil 1
Soil 2
Soil 2
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2

31
32
33
34
35
36
37
39
40
41
42
43
44
45
46
47
48
49
50
51
52
54
56
57
58
59
60

Streptomyces
Streptomyces
Streptomyces
Nocardia
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Nocardia
Nocardia
Streptomyces
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Antibioticus
Gardneri
Tumescens
Asteroides
Minoensis
aurantiogriseus
Matensis
griseorubens
Fradiae
Violascens
zaomyceticus
viridochromogenes
beijiangensis
intermedius
intermedius
albidoflavus
Matensis
griseoplanus
drozdowiczii
drozdowiczii
coelicoflavus
intermedius
intermedius
Sampsonii
Asteroides
Asteroides
Glebosus

SYE
SCA
AGS
AGS
SYE
SYE
SCA
SCA
SCA
SYE
AGS
SCA
AGS
SYE
SYE
SYE
SCA
SYE
SYE
AGS
AGS
SYE
SCA
SCA
AGS
SYE
AGS

Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 3
Method 1
Method 1
Method 3
Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 3
Method 3
Method 1
Method 1
Method 2
Method 2
Method 1
Method 1
Method 1
Method 1
Method 1

Soil 1
Soil 1
Soil 1
Soil 1
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 1
Soil 1
Soil 1

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
84
85
86
87
88

Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Brevibacterium
Streptomyces
Microbacterium
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
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hawaiiensis
Variabilis
drozdowiczii
drozdowiczii
drozdowiczii
griseoaurantiacus
intermedius
thermocarboxydus
viridobrunneus
intermedius
epidermidis
intermedius
ginsengiterrae
coelicoflavus
Gardneri
intermedius
malachitospinus
intermedius
aurantiacus
malachitospinus
Tendae
drozdowiczii
Tendae
Tendae
Gardneri
Praecox
turgidiscabies

SYE
SCA
AGS
AGS
AGS
AGS
AGS
AGS
AGS
AGS
AGS
AGS
AGS
SCA
AGS
SCA
AGS
SCA
SCA
AGS
SYE
SYE
SYE
SYE
AGS
SYE
AGS

Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 4
Method 4
Method 4
Method 4
Method 4
Method 1
Method 1
Method 1
Method 1
Method 3
Method 3
Method 3

Soil 1
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 1
Soil 2
Soil 1
Soil 2
Soil 2
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 1
Soil 2
Soil 1

89
90
91
92
93
94
95
96
97
98
99
100
101
104
105
106
107
108
109
110
111
113
114
115
116
117
118

Streptomyces
Streptomyces
Streptomyces
Gordonia
Rhodococcus
Streptomyces
Micrococcus
Streptomyces
Streptomyces
Nocardia
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Nocardia
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
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drozdowiczii
drozdowiczii
zaomyceticus
namibiensis
Opacus
glebosus
yunnanensis
griseorubens
Lividans
caverna
violascens
drozdowiczii
Griseus
coelicoflavus
malachitospinus
Libani
asteroides
spongiae
parvulus
olivoverticillatus
chartreusis
hawaiiensis
cinereospinus
intermedius
chartreusis
chartreusis
griseocarneus

AGS
AGS
AGS
SCA
SCA
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
AGS
AGS
AGS
SCA
AGS
AGS
AGS
AGS
AGS
SYE
SCA
SYE

Method 3
Method 3
Method 3
Method 3
Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 1
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3

Soil 2
Soil 2
Soil 2
Soil 1
Soil 1
Soil 1
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 2
Soil 1
Soil 1
Soil 1
TSF 3
Soil 1
Soil 1
Soil 1
Soil 1
Soil 1
TSF 1
TSF 1
TSF 1

121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147

Streptomyces
Rhodococcus
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Rhodococcus
Rhodococcus
Streptomyces
Streptomyces
Rhodococcus
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Agromyces
Rhodococcus
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cyanoalbus
erythropolis
Atratus
chartreusis
cinereorectus
diastatochromogenes
chartreusis
drozdowiczii
platensis
opacus
opacus
rishiriensis
drozdowiczii
opacus
angustmyceticus
drozdowiczii
purpurescens
exfoliatus
septatus
Rochei
angustmyceticus
olivoverticillatus
hirsutus
angustmyceticus
olivochromogenes
Lapidis
opacus

SYE
SCA
SYE
SYE
SCA
SCA
SCA
SYE
SYE
SCA
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA

Method 1
Method 1
Method 3
Method 3
Method 1
Method 3
Method 3
Method 1
Method 1
Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 3
Method 1
Method 1
Method 3
Method 1
Method 3
Method 3
Method 1
Method 3
Method 3
Method 1
Method 3

TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1
TSF 1

149
150
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
177

Arthrobacter
Streptomyces
Streptomyces
Streptomyces
Mycobacterium
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Mycobacterium
Gordonia
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kerguelensis
exfoliatus
Tendae
lavendulae
parafortuitum
malachitospinus
pactum
olivaceus
malachitospinus
olivaceus
praecox
malachitospinus
griseoaurantiacus
griseoplanus
malachitospinus
malachitospinus
malachitospinus
griseoplanus
viridochromogenes
malachitospinus
malachitospinus
bungoensis
psammoticus
malachitospinus
rameus
obuense
Terrae

SYE
SCA
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SYE
SYE
SCA

Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1

TSF 1
TSF 1
TSF 1
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 2
TSF 3
TSF 2
TSF 2
TSF 2

178
180
181
182
183
185
186
187
188
189
317
318
319
320
321
322
323
334
335
336
337
338
339
340
341
342
343

Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Nocardioides
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Isoptericola
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
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rameus
champavatii
griseoplanus
flavogriseus
parvus
viridochromogenes
microflavus
olivaceus
alpinus
galbus
praecox
endophyticus
endophyticus
narbonensis
variabilis
philanthi
philanthi
psammoticus
lydicus
costaricanus
shenzhensis
gardneri
kanamyceticus
drozdowiczii
drozdowiczii
endophyticus
shenzhensis

SCA
SYE
SYE
SYE
SYE
SCA
SCA
SCA
SYE
SCA
SYE
SCA
SCA
SYE
SYE
SCA
SYE
SCA
SCA
SYE
SYE
SYE
SYE
SCA
SCA
SYE
SYE

Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 1
Method 3
Method 3
Method 3
Method 3
Method 1
Method 3
Method 3
Method 3
Method 3
Method 3
Method 3
Method 3
Method 1
Method 3
Method 3
Method 1
Method 1

TSF 2
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 3
TSF 2
SIS 19
SIS 19
SIS 19
SIS 19
SIS 19
SIS 19
SIS 19
TSF 7
TSF 7
TSF 7
TSF 7
SIS 19
SIS 19
SIS 19
SIS 19
SIS 19
TSF 7

344
345
346
347
348
356
357
358
408
409
410
411
412
435
436
437
445
446
447
448
449
450
451
452
453
454
455

Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Streptomyces
Mycobacterium
Nocardioides
Mycobacterium
Rhodococcus
Streptomyces
Streptomyces
Mycobacterium
Mycobacterium
Microbacterium
Streptomyces
Agromyces
Leifsonia
Streptomyces
Rhodococcus
Rhodococcus
Streptomyces
Mycobacterium
Rhodococcus
Williamsia
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lydicus
lydicus
ginsengisoli
prasinopilosus
indiaensis
malachitospinus
violascens
javensis
neoaurum
sp.
obuense
equi
philanthi
zaomyceticus
obuense
obuense
foliorum
sp.
sp.
sp.
piomogenus
sp.
equi
sp.
rhodesiae
equi
sp.

SYE
SYE
SYE
SYE
SYE
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SCA
SYE
SYE
SYE
SYE
SYE
SCA
SYE
SYE
SCA
SYE
SYE
SCA
SYE
SYE

Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 3
Method 3
Method 1
Method 3
Method 3
Method 3
Method 3
Method 3
Method 3
Method 1
Method 1
Method 1
Method 1
Method 1
Method 3
Method 3
Method 1
Method 3

TSF 7
TSF 7
TSF 7
TSF 7
TSF 7
CWR 23
CWR 31
CWR 27
TSF 2
TSF 7
TSF 7
TSF 7
SIS 19
SIS 19
TSF 2
TSF 2
SHH 18
SHH 18
SHH 18
TSF 7
TSF 7
SHH 18
TSF 4
SHH 18
TSF 4
TSF 4
SHH 18

475
476
478
571
572
573
574
575
586
587
588
589
590
591
657
658
682
683
684
707
708
709
710
711
712
713
714

Leifsonia
Microbacterium
Mycobacterium
Mycobacterium
Rhodococcus
Mycobacterium
Mycobacterium
Mycobacterium
Micromonospora
Mycobacterium
Mycobacterium
Leifsonia
Nocardia
Mycobacterium
Mycobacterium
Mycobacterium
Gordonia
Rhodococcus
Pseudonocardia
Mycobacterium
Promicromonospora
Mycobacterium
Rhodococcus
Nocardia
Nocardia
Micrococcus
Rhodococcus
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sp.
azadirachtae
neglectum
poriferae
equi
poriferae
psychrotolerans
aichiense
tulbaghiae
chlorophenolicum
madagascariense
shinshuensis
nova
sp.
rhodesiae
sp.
terrae
rhodochrous
kujensis
sp.
sp.
sp.
sp.
oleivorans
rhamnosiphila
sp.
sp.

SCA
SCA
SCA
SYE
SCA
SYE
SYE
SCA
SCA
SCA
SCA
SYE
SCA
SCA
SCA
SYE
SCA
SYE
SYE
SCA
SYE
SCA
SYE
SYE
SYE
Dishaw
SCA

Method 1
Method 3
Method 3
Method 1
Method 1
Method 3
Method 1
Method 1
Method 1
Method 1
Method 3
Method 3
Method 1
Method 1
Method 3
Method 1
Method 3
Method 1
Method 1
Method 1
Method 3
Method 1
Method 3
Method 1
Method 1
N/A
Method 3

TSF 5
TSF 5
TSF 5
TSF 9
TSF 9
TSF 9
TSF 9
TSF 9
TSF 4
TSF 5
TSF 7
TSF 4
TSF 2
TSF 4
TSF 4
TSF 9
HRT 79
HRT 79
HRT 79
SIS 20
TSF 12
TSF 12
TSF 13
TSF 10
TSF 10
Seasquirt
TSF 13

Sample
1 (Control)
1 (DNMTi)
5 (Control)
5 (DNMTi)
6 (Control)
6 (DNMTi)
7 (Control)
7 (DNMTi)
8 (Control)
8 (DNMTi)
10 (Control)
10 (DNMTi)
11 (Control)
11 (DNMTi)
12 (Control)
12 (DNMTi)
13 (Control)
13 (DNMTi)
14 (Control)
14 (DNMTi)
15 (Control)
15 (DNMTi)
16 (Control)
16 (DNMTi)
17 (Control)
17 (DNMTi)

E. faecium
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

S. aureus
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
4 μg mL -1
10 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
25 μg mL -1
2 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
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K. pneumoniae
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

A. baumannii
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

P. aeruginosa
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

E. cloacae
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

18 (Control)
18 (DNMTi)
19 (Control)
19 (DNMTi)
20 (Control)
20 (DNMTi)
21 (Control)
21 (DNMTi)
22 (Control)
22 (DNMTi)
25 (Control)
25 (DNMTi)
26 (Control)
26 (DNMTi)
27 (Control)
27 (DNMTi)
29 (Control)
29 (DNMTi)
30 (Control)
30 (DNMTi)
31 (Control)
31 (DNMTi)
32 (Control)
32 (DNMTi)
33 (Control)
33 (DNMTi)
34 (Control)
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0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
119

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

34 (DNMTi)
35 (Control)
35 (DNMTi)
36 (Control)
36 (DNMTi)
37 (Control)
37 (DNMTi)
39 (Control)
39 (DNMTi)
40 (Control)
40 (DNMTi)
41 (Control)
41 (DNMTi)
42 (Control)
42 (DNMTi)
43 (Control)
43 (DNMTi)
44 (Control)
44 (DNMTi)
45 (Control)
45 (DNMTi)
46 (Control)
46 (DNMTi)
47 (Control)
47 (DNMTi)
48 (Control)
48 (DNMTi)
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100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
25 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
120

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

49 (Control)
49 (DNMTi)
50 (Control)
50 (DNMTi)
51 (Control)
51 (DNMTi)
52 (Control)
52 (DNMTi)
54 (Control)
54 (DNMTi)
56 (Control)
56 (DNMTi)
57 (Control)
57 (DNMTi)
58 (Control)
58 (DNMTi)
59 (Control)
59 (DNMTi)
60 (Control)
60 (DNMTi)
61 (Control)
61 (DNMTi)
62 (Control)
62 (DNMTi)
64 (Control)
64 (DNMTi)
65 (Control)

Table A - 2. (Continued)
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
25 μg mL -1
50 μg mL -1
25 μg mL -1
50 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
121

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

65 (DNMTi)
66 (Control)
66 (DNMTi)
67 (Control)
67 (DNMTi)
68 (Control)
68 (DNMTi)
69 (Control)
69 (DNMTi)
70 (Control)
70 (DNMTi)
71 (Control)
71 (DNMTi)
72 (Control)
72 (DNMTi)
73 (Control)
73 (DNMTi)
74 (Control)
74 (DNMTi)
75 (Control)
75 (DNMTi)
76 (Control)
76 (DNMTi)
77 (Control)
77 (DNMTi)
78 (Control)
78 (DNMTi)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
25 μg mL -1
0 μg mL -1
100 μg mL -1
10 μg mL -1
100 μg mL -1
200 μg mL -1
0 μg mL -1
100 μg mL -1
100 μg mL -1
200 μg mL -1
122

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

79 (Control)
79 (DNMTi)
80 (Control)
80 (DNMTi)
81 (Control)
81 (DNMTi)
82 (Control)
82 (DNMTi)
84 (Control)
84 (DNMTi)
85 (Control)
85 (DNMTi)
86 (Control)
86 (DNMTi)
87 (Control)
87 (DNMTi)
88 (Control)
88 (DNMTi)
89 (Control)
89 (DNMTi)
90 (Control)
90 (DNMTi)
91 (Control)
91 (DNMTi)
92 (Control)
92 (DNMTi)
93 (Control)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
20 μg mL -1
0 μg mL -1
100 μg mL -1
100 μg mL -1
100 μg mL -1
12.5 μg mL -1
0 μg mL -1
100 μg mL -1
20 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
123

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

93 (DNMTi)
95 (Control)
95 (DNMTi)
96 (Control)
96 (DNMTi)
97 (Control)
97 (DNMTi)
98 (Control)
98 (DNMTi)
99 (Control)
99 (DNMTi)
100 (Control)
100 (DNMTi)
101 (Control)
101 (DNMTi)
104 (Control)
104 (DNMTi)
105 (Control)
105 (DNMTi)
106 (Control)
106 (DNMTi)
107 (Control)
107 (DNMTi)
108 (Control)
108 (DNMTi)
109 (Control)
109 (DNMTi)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
10 μg mL -1
4 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
10 μg mL -1
10 μg mL -1
124

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

110 (Control)
110 (DNMTi)
111 (Control)
111 (DNMTi)
112 (Control)
112 (DNMTi)
113 (Control)
113 (DNMTi)
114 (Control)
114 (DNMTi)
115 (Control)
115 (DNMTi)
116 (Control)
116 (DNMTi)
117 (Control)
117 (DNMTi)
118 (Control)
118 (DNMTi)
121 (Control)
121 (DNMTi)
122 (Control)
122 (DNMTi)
123 (Control)
123 (DNMTi)
124 (Control)
124 (DNMTi)
125 (Control)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

100 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
125

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
100 μg mL -1
100 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

125 (DNMTi)
126 (Control)
126 (DNMTi)
127 (Control)
127 (DNMTi)
128 (Control)
128 (DNMTi)
129 (Control)
129 (DNMTi)
130 (Control)
130 (DNMTi)
131 (Control)
131 (DNMTi)
132 (Control)
132 (DNMTi)
133 (Control)
133 (DNMTi)
134 (Control)
134 (DNMTi)
135 (Control)
135 (DNMTi)
136 (Control)
136 (DNMTi)
137 (Control)
137 (DNMTi)
138 (Control)
138 (DNMTi)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
126

0 μg mL -1
0 μg mL -1
200 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

139 (Control)
139 (DNMTi)
140 (Control)
140 (DNMTi)
141 (Control)
141 (DNMTi)
142 (Control)
142 (DNMTi)
143 (Control)
143 (DNMTi)
144 (Control)
144 (DNMTi)
145 (Control)
145 (DNMTi)
146 (Control)
146 (DNMTi)
147 (Control)
147 (DNMTi)
149 (Control)
149 (DNMTi)
150 (Control)
150 (DNMTi)
152 (Control)
152 (DNMTi)
153 (Control)
153 (DNMTi)
154 (Control)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
127

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

154 (DNMTi)
155 (Control)
155 (DNMTi)
156 (Control)
156 (DNMTi)
157 (Control)
157 (DNMTi)
158 (Control)
158 (DNMTi)
159 (Control)
159 (DNMTi)
160 (Control)
160 (DNMTi)
161 (Control)
161 (DNMTi)
162 (Control)
162 (DNMTi)
163 (Control)
163 (DNMTi)
164 (Control)
164 (DNMTi)
165 (Control)
165 (DNMTi)
166 (Control)
166 (DNMTi)
713 (Control)
713 (DNMTi)

Table A - 2. (Continued)
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
128

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1
0 μg mL -1

